WO2022068810A1 - 抗Claudin18.2和CD3的双特异性抗体以及其用途 - Google Patents

抗Claudin18.2和CD3的双特异性抗体以及其用途 Download PDF

Info

Publication number
WO2022068810A1
WO2022068810A1 PCT/CN2021/121286 CN2021121286W WO2022068810A1 WO 2022068810 A1 WO2022068810 A1 WO 2022068810A1 CN 2021121286 W CN2021121286 W CN 2021121286W WO 2022068810 A1 WO2022068810 A1 WO 2022068810A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequence
antibody
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/121286
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
周帅祥
管哲
伍伟伟
高亚荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics Suzhou Co Ltd
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Priority to AU2021352532A priority Critical patent/AU2021352532B2/en
Priority to CN202180066494.1A priority patent/CN116323676A/zh
Priority to US18/246,939 priority patent/US20230357389A1/en
Priority to JP2023519492A priority patent/JP2023544143A/ja
Priority to EP21874470.4A priority patent/EP4223778A4/en
Priority to KR1020237014540A priority patent/KR20230079165A/ko
Priority to CA3200865A priority patent/CA3200865A1/en
Publication of WO2022068810A1 publication Critical patent/WO2022068810A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to bispecific antibodies that specifically bind to Claudin18.2 and CD3 and compositions containing the same. Furthermore, the present invention relates to nucleic acids encoding said antibodies and host cells comprising the same, and related uses. The present invention also relates to the therapeutic and diagnostic uses of these antibodies and antibody fragments.
  • Claudins are a family of proteins that are important building blocks for the formation of tight junctions in cells. They establish intercellular barriers that control the flow of molecules between cells, which can control the flow of molecules between cells.
  • the Claudins family proteins have a four-transmembrane domain whose N- and C-termini are both included in the cytoplasm.
  • Different Claudin proteins are expressed in different tissues, and their functional changes are related to the formation of cancer in various tissues. For example, Claudin-1 is expressed in colon cancer and has prognostic value, Claudin-18 is highly expressed in gastric cancer and pancreatic cancer, and Claudin- 10 is highly expressed in hepatocellular carcinoma.
  • Claudins, as cell membrane surface proteins, are useful targets for various therapeutic strategies.
  • Isoform 2 of Claudin-18 (Claudin 18.2 or CLDN18.2) is a highly selective cell lineage marker whose expression in normal tissues is strictly restricted to gastric mucosal differentiated epithelial cells, but not in the gastric stem cell region.
  • CLDN18.2 is expressed in a considerable part of primary gastric cancer, and its expression level is retained in gastric metastatic cancer tissue.
  • pancreatic cancer which is an ideal target molecule for the treatment of these cancers (Singh, P., Toom, S. & Huang, Y. Anti-CLDN18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol 10, 105 (2017). https://doi.org/10.1186/s13045-017-0473-4 ).
  • CD3 is a homodimeric or heterodimeric antigen expressed on T cells that binds to the T cell receptor complex (TCR) and is required for T cell activation.
  • Functional CD3 is formed by the dimeric association of two of four different chains: epsilon, zeta, delta, and gamma.
  • the CD3 dimer arrangement contains ⁇ / ⁇ , ⁇ / ⁇ and ⁇ / ⁇ .
  • Antibodies against CD3 have been shown to aggregate CD3 on T cells, causing T cell activation in a manner similar to the engagement of TCR by peptide-loaded MHC molecules. Accordingly, anti-CD3 antibodies have been proposed for therapeutic purposes involving T cell activation.
  • bispecific antibodies that can bind to CD3 and target tumor surface antigens can engage tumor cells and T cells, thereby directly activating T cells, releasing granzymes, perforin and cytokines to kill tumors, thereby achieving tumor-inhibiting effects.
  • CLDN18.2 is highly expressed in gastric cancer, pancreatic cancer, gastroesophageal junction cancer, etc., so the therapeutic purpose can be achieved by developing bispecific antibodies that bind both CD3 and Claudin18.2.
  • the invention provides bispecific antibodies, wherein the antibody comprises two binding domains, wherein the first binding domain specifically binds CLDN18.2 and the second binding domain specifically binds CD3.
  • the first binding domain of the invention that specifically binds CLDN18.2 is fully human, and/or the second binding domain is humanized.
  • the bispecific antibodies of the invention are bispecific antibodies of IgG-like structure.
  • the present invention relates to the following embodiments:
  • a bispecific antibody comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain specifically binds CLDN18.2, and the second antigen-binding domain specifically binds CD3, wherein the first antigen-binding domain specifically binds to CLDN18.2;
  • An antigen binding domain comprising the three complementarity determining regions A1-HCDR1, A1-HCDR2 and A1-HCDR3 contained in A1-VH as shown in SEQ ID NO:4, and VL as shown in SEQ ID NO:9
  • the second antigen binding domain comprises the three contained in A2-VH as shown in SEQ ID NO: 30, 22 or 32
  • the first antigen binding domain comprises A1-HCDR1, A1-HCDR2, A1-HCDR3, respectively, as shown in the following amino acid sequences: SEQ ID NOs: 1, 2, and 3, and A1-LCDR1, A1-LCDR1, A1-LCDR2 and A1-LCDR3: SEQ ID NOs: 6, 7 and 8; and
  • the second antigen binding domain comprises
  • the first antigen binding domain comprises a heavy chain variable region and/or a light chain variable region, wherein the heavy chain variable region
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 4; or
  • amino acid changes comprising 1 or more (preferably no more than 10, more preferably no more than 5, 4, 3, 2, 1) amino acid changes (preferably The amino acid sequence of amino acid substitutions, more preferably conservative substitutions of amino acids, consists of said amino acid sequence, preferably, said amino acid changes do not occur in the CDR regions; and/or
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 9; or
  • amino acid changes (preferably no more than 1) compared to the amino acid sequence selected from SEQ ID NO: 9
  • amino acid sequence of amino acid substitutions more preferably conservative substitutions of amino acids, consists of the amino acid sequence, preferably, the amino acid changes do not occur in the CDR regions.
  • the second antigen binding domain comprises a heavy chain variable region and/or a light chain variable region, wherein the heavy chain variable region
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 30, 22 or 32; or
  • amino acid sequence of amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions) consists of the amino acid sequence, preferably, the amino acid changes do not occur in the CDR regions;
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 27; or
  • amino acid changes (preferably) compared to the amino acid sequence selected from SEQ ID NO: 27
  • amino acid sequence of amino acid substitutions more preferably conservative substitutions of amino acids, consists of the amino acid sequence, preferably, the amino acid changes do not occur in the CDR regions.
  • the antibody of any one of embodiments 1-4 further comprising a heavy chain constant region and/or a light chain constant region.
  • the antibody of any one of embodiments 1-5 which is a bispecific antibody of an IgG-like structure.
  • the antibody of any one of embodiments 1-6, wherein the heavy chain constant region of the antibody is from IgGl or IgG2 or IgG3 or IgG4, preferably IgGl.
  • the antibody of any one of embodiments 1-6 comprising two heavy chain constant regions, wherein one heavy chain constant region A1-HC is linked to the heavy chain variable region A1-VH of the first antigenic domain to form a The heavy chain of the CDLN18.2 binding part, and the other heavy chain constant region A2-HC is linked to the heavy chain variable region A2-VH of the second antigen binding domain to form the heavy chain of the CD3 binding part, and contains 2 light Chain constant regions, wherein one light chain constant region A1-LC is linked to the light chain variable region A1-VL of the first antigen domain to form the light chain of the binding moiety to CLDN18.8, and the other light chain constant region A2-LC Linked to the light chain variable region A2-VL of the second antigen binding domain constitutes the light chain of the CD3 binding moiety.
  • A1-HC can be the same or different from A2-HC
  • A1-LC can be the same or different from A2-LC
  • amino acids comprising 1 or more (preferably no more than 20 or 10, more preferably no more than 5, 4, 3, 2, 1) amino acids compared to the amino acid sequence selected from the group consisting of SEQ ID NO: 37 an altered (preferably amino acid substitution, more preferably conservative amino acid substitution) amino acid sequence or consisting of said amino acid sequence; and/or
  • amino acid sequence comprising 1 or more (preferably no more than 20 or 10, more preferably no more than 5, 4, 3, 2, 1) amino acids compared to the amino acid sequence selected from the group consisting of SEQ ID NO: 38
  • the amino acid sequence that is altered is or consists of said amino acid sequence.
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 41, 39 or 42; or
  • amino acid sequences comprising 1 or more (preferably no more than 20 or 10, more preferably no more than 5, 4, 3, 2, 1) compared to the amino acid sequence selected from SEQ ID NO: 41, 39 or 42 an amino acid sequence of amino acid changes (preferably amino acid substitutions, more preferably conservative substitutions of amino acids) of or consisting of said amino acid sequences; and/or
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 40; or
  • amino acid sequence comprising 1 or more (preferably no more than 20 or 10, more preferably no more than 5, 4, 3, 2, 1) amino acids compared to the amino acid sequence selected from the group consisting of SEQ ID NO: 40
  • the amino acid sequence that is altered is or consists of said amino acid sequence.
  • An isolated nucleic acid encoding a light chain variable region or a heavy chain variable region, or a light chain or a heavy chain, of the antibody of any one of embodiments 1 to 12.
  • a host cell comprising the nucleic acid of embodiment 13 or the vector of embodiment 14, preferably, the host cell is prokaryotic or eukaryotic, more preferably selected from yeast cells, mammalian cells (eg 293 cells or CHO cells) cells, such as CHO-S cells or HEK293 cells) or other cells suitable for the production of antibodies or antigen-binding fragments thereof.
  • a method of making an antibody or antigen-binding fragment thereof that binds CLDN18.2 comprising culturing the host cell of embodiment 15 under conditions suitable for expressing a nucleic acid encoding the antibody of any one of embodiments 1 to 12, Optionally the antibody or antigen-binding fragment thereof is isolated, and optionally the method further comprises recovering the antibody from the host cell.
  • a pharmaceutical composition comprising the CLDN18.2-binding antibody or antigen-binding fragment thereof of any one of embodiments 1 to 12, and optionally one or more other therapeutic agents, such as chemotherapeutic agents, angiogenesis-inhibiting agents agents, cytokines, cytotoxic agents, other antibodies, small molecule drugs or immunomodulators (eg, immune checkpoint inhibitors or agonists), and optionally, pharmaceutical excipients.
  • therapeutic agents such as chemotherapeutic agents, angiogenesis-inhibiting agents agents, cytokines, cytotoxic agents, other antibodies, small molecule drugs or immunomodulators (eg, immune checkpoint inhibitors or agonists), and optionally, pharmaceutical excipients.
  • a pharmaceutical combination comprising the antibody or antigen-binding fragment thereof of any one of embodiments 1 to 12, and one or more other therapeutic agents, such as chemotherapeutic agents, angiogenesis inhibitors, cytokines, cytotoxic agents, Other antibodies, small molecule drugs or immunomodulators (eg immune checkpoint inhibitors or agonists).
  • therapeutic agents such as chemotherapeutic agents, angiogenesis inhibitors, cytokines, cytotoxic agents, Other antibodies, small molecule drugs or immunomodulators (eg immune checkpoint inhibitors or agonists).
  • a method of preventing or treating a tumor in a subject comprising administering to the subject an effective amount of the antibody or antigen-binding fragment thereof of any one of embodiments 1 to 12, or the medicament of embodiment 17
  • the tumor is a cancer
  • the cancer has elevated levels (eg nucleic acid or protein levels) of CLDN18.2, eg the cancer is pancreatic or gastric or gastroesophageal borderline cancer.
  • the method further comprises administering to the patient one or more therapies, such as a therapeutic modality and/or other therapeutic agent, preferably the therapeutic modality includes radiation therapy or surgery , or therapeutic agents include chemotherapeutic agents, angiogenesis inhibitors, cytokines, cytotoxic agents, other antibodies, small molecule drugs, or immunomodulatory agents (eg, immune checkpoint inhibitors or agonists).
  • therapies such as a therapeutic modality and/or other therapeutic agent, preferably the therapeutic modality includes radiation therapy or surgery , or therapeutic agents include chemotherapeutic agents, angiogenesis inhibitors, cytokines, cytotoxic agents, other antibodies, small molecule drugs, or immunomodulatory agents (eg, immune checkpoint inhibitors or agonists).
  • Figure 1 shows that the HB37A6 antibody specifically binds to CLDN18.2 on the cell surface.
  • Figure 2 shows that the HB37A6 antibody does not bind to CLDN18.1 on the cell surface.
  • Figure 3 shows the binding of HB37A6 antibody to gastric cancer cell line NUGC-4, gastric cancer cell line KATO III-hCLDN18.2 and pancreatic cancer cell line DAN-G-hCLDN18.2.
  • Figure 4 shows the anti-tumor effect of HB37A6 antibody in pancreatic cancer mouse model.
  • Figure 5 shows the antitumor effect of HB37A6 antibody in gastric cancer mouse model.
  • Figure 6 shows the binding affinities of the CD3 mAbs Hzsp34.24, Hzsp34.87 and Hzsp34.97 at the cellular level.
  • Figure 7 shows the T cell activation capacity of the CD3 antibodies Hzsp34.24, Hzsp34.87 and Hzsp34.97.
  • Figure 8 shows a schematic diagram showing the structure of the bispecific antibody used in the examples.
  • FIG. 9 shows that the bispecific antibody of the present invention specifically kills CLDN18.2 positive gastric cancer cell NUGC-4.
  • FIG 10 shows that bispecific antibodies specifically kill CLDN18.2 positive pancreatic cancer cells DAN-GCLDN18.2.
  • FIG. 11 shows that bispecific antibodies did not non-specifically kill cells negative for CLDN18.2 expression.
  • Figure 12 shows bispecific antibody-dependent T cell-mediated cytokine release in NUGC-4.
  • Figure 13 shows bispecific antibody dependent T cell mediated cytokine release in DAN-G-CLDN18.2.
  • FIG. 14 shows CLDN18.2 expression-dependent bispecific antibody-mediated T cell activation.
  • Figure 15 shows the in vivo efficacy results of bispecific antibodies in a NUGC-4 gastric cancer humanized model.
  • Figure 16 shows the in vivo efficacy results of bispecific antibodies in a DAN-G-CLDN18.2 humanized model of pancreatic cancer.
  • Figure 17 shows the PK of bispecific antibodies in mice.
  • the term “comprising” or “comprising” means the inclusion of stated elements, integers or steps, but not the exclusion of any other elements, integers or steps.
  • the terms “comprising” or “comprising” are used, unless otherwise indicated, combinations of the stated elements, integers or steps are also encompassed.
  • reference to an antibody variable region that "comprises” a particular sequence is also intended to encompass antibody variable regions that consist of that particular sequence.
  • Claudin protein is the most important cytoskeletal protein that determines the structure of tight junctions between cells, is involved in adhesion junctions, and plays an important role in the metastasis and invasion of tumor cells.
  • Claudin protein is widely present in mammalian epithelial and endothelial cells, and its distribution is mainly on the side of epithelial cells and the plasma membrane of basal cells. Different Claudin proteins have their own specific expression in different tissues.
  • the Claudin18 (CLDN18) gene is located at 3q22.3, with a molecular weight of 24kDa and 261 amino acid residues.
  • CLDN18 or Claudin18 protein contains 2 extracellular Ring and 4 transmembrane zones.
  • the two isoforms of human CLDN18 or Claudin18 protein are Claudin18.1 or CLDN18.1 (UniProt ID: P56856-1), and Claudin18.2 or CLDN18.2 (UniProt ID: P56856-2), respectively.
  • Loop1 extracellular loop 1
  • CLDN18.1 and CLDN18.2 only 8 amino acids differ.
  • the interspecies sequence homology of the two isoforms of CLDN18 is also very high.
  • CLDN18.2 the extracellular loop 1 of CLDN18.2 is completely identical in sequence in different species such as human, mouse, and macaque, and the homology of CLDN18.2 protein between human and mouse reaches 84%, indicating that the sequence of CLDN18.2 protein is extremely conserved (O. Tureci. et al., Gene 481:83-92, 2011).
  • CLDN18.2, or any variants and isoforms thereof, can be isolated from cells or tissues in which they are naturally expressed, or recombinantly produced using techniques well known in the art and/or those described herein.
  • the CLDN18.2 described herein is human CLDN18.2.
  • anti-CLDN18.2 antibody refers to an antibody capable of binding with sufficient affinity (human) CLDN18.2 so that the antibody can be used as a therapeutic targeting (human) CLDN18.2.
  • the (human) CLDN18.2 antibody binds (human) CLDN18.2 with high affinity in vitro or in vivo.
  • the (human) CLDN18.2 antibody does not bind CLDN18.1.
  • the (human) CLDN18.2 antibody binds to cells expressing CLDN18.2 but not to cells expressing CLDN18.1.
  • the binding is measured, eg, by radioimmunoassay (RIA), biofilm thin layer interferometry (BLI), MSD assay or surface plasmon resonance (SPR) or flow cytometry.
  • CD3 refers to an antigen expressed on T cells as part of the multimolecular T cell receptor (TCR) and which is a homodimer formed by two of the following four receptor chains Or heterodimers: CD3- ⁇ , CD3- ⁇ , CD3- ⁇ and CD3- ⁇ .
  • Human CD3- ⁇ n contains the amino acid sequence described in UniProtKB/Swiss-Prot: P07766.2.
  • Human CD3-delta (hCD3delta) comprises the amino acid sequence described in UniProtKB/Swiss-Prot: P04234.1.
  • the CD3 of the present invention refers to CD3 from human or cynomolgus monkey.
  • the term "antibody that binds CD3" or "anti-CD3 antibody” includes antibodies and antigen-binding fragments thereof that specifically recognize or bind to a single CD3 subunit (eg, epsilon, delta, gamma, or zeta), as well as Dimeric complexes of two CD3 subunits (eg, gamma/epsilon, delta/epsilon, and zeta/zeta CD3 dimers) and antibodies and antigen-binding fragments thereof linked thereto.
  • the antibodies and antigen-binding fragments of the invention can bind to soluble CD3, bound CD3, and/or cell surface expressed CD3.
  • Soluble CD3 comprises native CD3 protein as well as recombinant CD3 protein variants, eg, monomeric and dimeric CD3 structures that lack transmembrane domains or that are otherwise not bound to cell membranes.
  • the present invention provides antibodies that bind to human and cynomolgus monkey CD3 with low or undetectable binding affinity, thereby enabling the activation of human and cynomolgus monkey T cells.
  • the binding is measured, for example, by radioimmunoassay (RIA), biofilm thin layer interferometry (BLI), MSD assay or surface plasmon resonance (SPR) or flow cytometry.
  • cell surface expressed CD3 refers to one or more CD3 proteins that are expressed on the cell surface in vivo or in vitro such that at least a portion of the CD3 protein is exposed on the extracellular side of the cell membrane and is accessible to the antigen-binding portion of the antibody .
  • Cell surface expressed CD3 includes CD3 protein within the context of a functional T cell receptor included in the cell membrane.
  • cell surface expressed CD3 encompasses CD3 protein expressed as part of a homodimer or heterodimer (eg, delta/epsilon, gamma/epsilon and zeta/zeta CD3 dimers) on the cell surface.
  • Effector cells include effector T cells (T lymphocytes) such as CD4+ T cells, CD8+ T cells, Th1, Th2 and regulatory T cells (Tregs). Effector cells may also include natural killer cells, macrophages, granulocytes, plasma cells or B cells (lymphocytes).
  • T lymphocytes such as CD4+ T cells, CD8+ T cells, Th1, Th2 and regulatory T cells (Tregs). Effector cells may also include natural killer cells, macrophages, granulocytes, plasma cells or B cells (lymphocytes).
  • multispecific antibody refers to an antibody that is at least bispecific, ie the antibody comprises at least a first binding domain and a second binding domain, wherein the first binding domain binds a target or antigen and The second binding domain binds another antigen or target.
  • the antibodies according to the present invention comprise specificities for at least two different antigens or targets.
  • Antibodies according to the invention also encompass multispecific antibodies comprising multiple binding domains/binding sites, such as trispecific antibodies, wherein the antibody comprises three binding domains.
  • Bispecific antibody formats comprise IgG-like and non-IgG-like antibodies (Fan et al. (2015) Journal of Hematology & Oncology. 8:130).
  • the most common type of IgG-like antibody contains two Fab regions and one Fc region, and the heavy and light chains of each Fab can be derived from separate monoclonal antibodies.
  • Non-IgG-like bispecific antibodies lacking an Fc region, each antigen- or target-binding domain of which can be a Fab, a single-chain variable fragment (scFv), or a fusion of variable domains that mimic two antibodies
  • the different binding domains are linked together by peptide linkers, chemical conjugation, non-covalent linkages, or other means.
  • These formats contain bispecific T-cell adaptors (BiTEs).
  • Bispecific antibodies of the invention can be prepared using any bispecific antibody format or technique.
  • an antibody or fragment thereof having a first antigen-binding specificity can be functionally linked (eg, by chemical coupling) to one or more other molecular entities, such as another antibody or antibody fragment having a second antigen-binding specificity. association, genetic fusion, non-covalent association, or otherwise) to generate bispecific antibodies.
  • bispecific formats that can be used in the context of the present invention include, but are not limited to, the following: scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, tetra-hybrid Quadroma, knobs-into-holes, common light chains (eg, common light chains with knob-in holes, etc.), CrossMab, CrossFab, (SEED)body, Duobody, IgG1/IgG2, dual-acting Fab ( DAF)-IgG and Mab 2 bispecific format.
  • scFv-based or diabody bispecific formats IgG-scFv fusions, dual variable domain (DVD)-Ig, tetra-hybrid Quadroma, knobs-into-holes, common light chains (eg, common light chains with knob-in holes, etc.), CrossMab, CrossFab, (SEED)body, Duobody, IgG1/
  • linker refers to any molecule that enables the direct linking of different parts of a bispecific antibody.
  • linkers that establish covalent linkages between different antibody moieties include peptide linkers and non-proteinaceous polymers including, but not limited to, polyethylene glycol (PEG), polypropylene glycol, polyoxyalkylene or polyethylene glycol, polypropylene glycol copolymer.
  • peptide linker refers to a sequence of amino acids, wherein said sequence joins the amino acid sequence of the first part of the antibody to the second part of the antibody.
  • a peptide linker can link a first (variable and/or binding) domain of an antibody to a second variable and/or binding) domain.
  • a peptide linker can also link one part of the antibody to another part of the antibody, such as linking an antigen binding domain to an Fc domain or fragment thereof.
  • the peptide linker is of a length sufficient to connect the two entities in such a way that they maintain their conformations relative to each other such that the desired activity is not hindered.
  • the peptide linker may or may not consist primarily of the following amino acid residues: Gly, Ser, Ala, or Thr.
  • Useful linkers include glycine-serine polymers including, for example, (GS) n , (GSGGS) n , (GGGGS) n , (GGGS) n and (GGGGS)nG, where n is at least 1 (and preferably 2, 3, 4, 5, 6, 7, 8, 9, 10).
  • Useful linkers also include glycine-alanine polymers, alanine-serine polymers, and other flexible linkers.
  • valency denotes the presence of a specified number of binding sites in an antibody molecule.
  • bivalent, trivalent, tetravalent respectively indicate the presence of two, three or four binding sites in the antibody construct.
  • Bispecific antibodies according to the invention are at least bivalent and may be multivalent, eg bivalent, trivalent, tetravalent or hexavalent.
  • binding domain refers to any portion of a bispecific antibody that binds a particular target or antigen.
  • the binding domain is the antigen binding site.
  • the binding domain can be, for example, an antibody or immunoglobulin itself or a fragment of an antibody.
  • Such a binding domain may or may not have tertiary structure independent of the remainder of the BsAB, and may or may not bind its target as a separate entity.
  • each antigen binding domain of a bispecific antibody includes a heavy chain variable region VH and a light chain variable region VL.
  • VH, VL or CDR of the first antigen binding domain may be denoted by the prefix "A1”
  • the second antigen binding domain The VH, VL or CDR can be represented by the prefix "A2".
  • the heavy chain CDRs (HCDRs) of the first antigen binding domain may be referred to herein as A1-HCDR1, A1-HCDR2 and A1-HCDR3; and the heavy chain CDRs of the second antigen binding domain may be referred to herein as A2-HCDR1, A2-HCDR2 and A2-HCDR3.
  • the heavy chain variable region VH of the first antigen binding domain is referred to herein as A1-VH
  • the heavy chain variable region VH of the second antigen binding domain is referred to herein as A2-VH.
  • the light chain CDRs (HCDRs) of the first antigen binding domain may be referred to herein as A1-LCDR1, A1-LCDR2 and A1-LCDR3; and the light chain CDRs of the second antigen binding domain may be referred to herein as A2- LCDR1, A2-LCDR2, and A2-LCDR3.
  • the light chain variable region VL of the first antigen binding domain is referred to herein as A1-VL
  • the light chain variable region VL of the second antigen binding domain is referred to herein as A2-VL.
  • antibody fragment includes a portion of an intact antibody.
  • the antibody fragment is an antigen-binding fragment.
  • an "antigen-binding fragment” refers to a molecule other than an intact antibody that comprises a portion of the intact antibody and binds the antigen to which the intact antibody binds.
  • antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab') 2 ; dAb (domain antibody); linear antibody; single chain antibody (eg, scFv); single domain antibody such as VHH ; a diabody or fragment thereof; or a camelid antibody.
  • antigen refers to a molecule that elicits an immune response. This immune response may involve antibody production or activation of specific immune cells, or both.
  • antigens can be derived from recombinant or genomic DNA.
  • epipe refers to the portion of an antigen (eg, CLDN18.2) that specifically interacts with an antibody molecule.
  • An antibody that binds the same or overlapping epitope as a reference antibody refers to an antibody that blocks 50%, 60%, 70%, 80%, 90% or 95% or more of said reference antibody in a competition assay with Binding of an antigen, conversely, a reference antibody blocks 50%, 60%, 70%, 80%, 90% or 95% more of the binding of the antibody to its antigen in a competition assay.
  • An antibody that competes with a reference antibody for binding to its antigen refers to an antibody that blocks more than 50%, 60%, 70%, 80%, 90% or 95% of the binding of said reference antibody to its antigen in a competition assay. Conversely, the reference antibody blocks more than 50%, 60%, 70%, 80%, 90% or 95% of the binding of the antibody to its antigen in a competition assay.
  • Numerous types of competitive binding assays can be used to determine whether one antibody competes with another, such as: solid-phase direct or indirect radioimmunoassay (RIA), solid-phase direct or indirect enzyme immunoassay (EIA), sandwich competition Determination.
  • An antibody that inhibits (eg competitively inhibits) the binding of a reference antibody to its antigen refers to an antibody that inhibits more than 50%, 60%, 70%, 80%, 90% or 95% of the binding of said reference antibody to its antigen . Conversely, the reference antibody inhibits more than 50%, 60%, 70%, 80%, 90% or 95% of the binding of the antibody to its antigen. Binding of an antibody to its antigen can be measured by affinity (eg, equilibrium dissociation constant). Methods for determining affinity are known in the art.
  • An antibody that exhibits the same or similar binding affinity and/or specificity as a reference antibody refers to an antibody capable of binding at least 50%, 60%, 70%, 80%, 90% or 95% or more of the reference antibody Affinity and/or specificity. This can be determined by any method known in the art for determining binding affinity and/or specificity.
  • CDR regions are loops in the variable domains of antibodies that are hypervariable in sequence and form structurally defined loops ("hypervariable loops") and/or contain antigen-contacting residues ( "antigen contact point”).
  • the CDRs are mainly responsible for binding to antigenic epitopes.
  • the CDRs of the heavy and light chains are commonly referred to as CDR1, CDR2 and CDR3, numbered sequentially from the N-terminus.
  • the CDRs located within the variable domains of antibody heavy chains are referred to as HCDR1, HCDR2 and HCDR3, while the CDRs located within the variable domains of antibody light chains are referred to as LCDR1, LCDR2 and LCDR3.
  • each CDR can be determined using any one or a combination of a number of well-known antibody CDR assignment systems, including Example: Chothia based on the three-dimensional structure of antibodies and topology of CDR loops (Chothia et al. (1989) Nature 342:877-883, Al-Lazikani et al, "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273, 927-948 (1997)), Kabat based on antibody sequence variability (Kabat et al., Sequences of Proteins of Immunological Interest, 4th ed., U.S.
  • the residues of each CDR are as follows.
  • a CDR can also be determined based on having the same Kabat numbering position as a reference CDR sequence (eg, any of the exemplary CDRs of the invention).
  • a residue position in an antibody variable region refers to the numbering system according to the Kabat ( Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).
  • the heavy chain variable region CDRs of the antibodies of the present invention are determined according to the following rules:
  • VH CDR1 was determined according to AbM rules; and VH CDR2 and 3 were determined according to Kabat rules.
  • the light chain variable region CDRs of the antibodies of the invention are determined according to Kabat's rules.
  • the heavy chain variable region CDRs of the antibodies of the invention are determined according to the following rules: VH CDR1 is determined according to the AbM rules; and VH CDR2 and 3 are both determined according to the Kabat rules; and the light chain variable region CDRs are determined according to the Kabat rules. .
  • the CDR boundaries of the variable region of the same antibody obtained based on different assignment systems may vary. That is, the CDR sequences of the variable regions of the same antibody defined under different assignment systems are different.
  • the scope of said antibody also covers antibodies whose variable region sequences comprise said specific CDR sequence, but due to the application of a different scheme (e.g. Different assignment system rules or combinations) cause the claimed CDR boundary to be different from the specific CDR boundary defined by the present invention.
  • Antibodies with different specificities have different binding sites for different antigens
  • CDRs vary from antibody to antibody, only a limited number of amino acid positions within CDRs are directly involved in antigen binding.
  • the minimal binding unit can be a sub-portion of a CDR.
  • the residues of the remainder of the CDR sequence can be determined by the structure and protein folding of the antibody, as will be apparent to those skilled in the art. Accordingly, the present invention also contemplates variants of any of the CDRs presented herein. For example, in a variant of a CDR, the amino acid residues of the smallest binding unit may remain unchanged, while the remaining CDR residues as defined by Kabat or Chothia may be replaced by conservative amino acid residues.
  • Fc region is used herein to define the CH2 and CH3 constant regions of immunoglobulin heavy chains and includes native sequence Fc regions and variant Fc regions.
  • the natural Fc region can bind to different Fc receptors on the surface of immune cells, which can cause CDC ⁇ ADCC ⁇ ADCP effector function.
  • Such effector functions generally require the association of an Fc region with a binding domain (eg, an antibody variable domain).
  • the Fc region is mutated to enhance its CDC ⁇ ADCC ⁇ ADCP effector function.
  • the Fc region is mutated to impair or delete its CDC ⁇ ADCC ⁇ ADCP effector function.
  • an antibody in the IgG format refers to the IgG format to which the heavy chain constant region of the antibody belongs.
  • the heavy chain constant regions of all antibodies of the same type are the same, and the heavy chain constant regions of antibodies of different types are different.
  • an antibody in the IgG4 format means that its heavy chain constant region is derived from IgG4, or an antibody in the IgG1 format means that its heavy chain constant region is derived from IgG1.
  • a “humanized” antibody refers to an antibody comprising amino acid residues from non-human CDRs and amino acid residues from human FRs.
  • a humanized antibody will comprise substantially all of at least one, usually two variable domains, wherein all or substantially all of the CDRs (eg, CDRs) correspond to those of the non-human antibody, and all Or substantially all of the FRs correspond to those of a human antibody.
  • a humanized antibody may optionally contain at least a portion of an antibody constant region derived from a human antibody.
  • a "humanized form" of an antibody (eg, a non-human antibody) refers to an antibody that has been humanized.
  • Human antibody or “fully human antibody” or “fully human antibody” are used interchangeably and refer to an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody derived from a human Either human cells are generated or derived from non-human sources using human antibody repertoires or other human antibody coding sequences. This definition of human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.
  • binding means that binding is selective for the antigen and can be distinguished from unwanted or non-specific interactions.
  • the ability of an antigen-binding site to bind to a specific antigen can be determined by enzyme-linked immunosorbent assay (ELISA) or conventional binding assays known in the art such as by radioimmunoassay (RIA) or biofilm interferometry or MSD method or surface plasmon resonance (SPR).
  • ELISA enzyme-linked immunosorbent assay
  • RIA radioimmunoassay
  • MSD biofilm interferometry
  • SPR surface plasmon resonance
  • therapeutic agent encompasses any substance that is effective in preventing or treating tumors, such as cancer, including chemotherapeutic agents, cytokines, angiogenesis inhibitors, cytotoxic agents, other antibodies, small molecule drugs, or immunomodulatory agents (eg immunosuppressants).
  • cytotoxic agent refers to a substance that inhibits or prevents cellular function and/or causes cell death or destruction.
  • “Chemotherapeutic agents” include chemical compounds useful in the treatment of cancer or diseases of the immune system.
  • small molecule drug refers to low molecular weight organic compounds capable of modulating biological processes.
  • Small molecule is defined as a molecule with a molecular weight of less than 10 kD, usually less than 2 kD and preferably less than 1 kD.
  • Small molecules include, but are not limited to, inorganic molecules, organic molecules, organic molecules containing inorganic components, molecules containing radioactive atoms, synthetic molecules, peptidomimetics, and antibody mimetics. As therapeutic agents, small molecules can be more cell permeable, less susceptible to degradation, and less susceptible to eliciting an immune response than macromolecules.
  • immunomodulator refers to a natural or synthetic active agent or drug that inhibits or modulates an immune response.
  • the immune response can be a humoral response or a cellular response.
  • Immunomodulators include immunosuppressants.
  • the immunomodulatory agents of the present invention include immune checkpoint inhibitors or immune checkpoint agonists.
  • an effective amount refers to an amount or dose of an antibody or fragment or composition or combination of the invention which, after administration to the patient in single or multiple doses, produces the desired effect in a patient in need of treatment or prevention.
  • a “therapeutically effective amount” refers to an amount effective to achieve the desired therapeutic result, at the required dose and for the required period of time.
  • a therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody fragment or composition or combination are outweighed by the therapeutically beneficial effects.
  • a “therapeutically effective amount” preferably inhibits a measurable parameter (eg, tumor volume) by at least about 40%, even more preferably at least about 50%, 55%, 60%, 65%, 70%, 75%, relative to an untreated subject %, 80%, 85%, 90% or even 100%.
  • prophylactically effective amount refers to an amount effective to achieve the desired prophylactic result, at the required dose and for the required period of time. Typically, a prophylactically effective amount will be less than a therapeutically effective amount because a prophylactic dose is administered in a subject prior to or at an earlier stage of the disease.
  • host cell refers to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells.
  • Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom, regardless of the number of passages. Progeny may not be identical in nucleic acid content to the parent cell, but may contain mutations. Included herein are mutant progeny screened or selected for the same function or biological activity in the originally transformed cell.
  • label refers to a compound or composition that is directly or indirectly conjugated or fused to an agent, such as a polynucleotide probe or antibody, and facilitates detection of the agent to which it is conjugated or fused.
  • the label can itself be detectable (eg, a radioisotope label or a fluorescent label) or, in the case of an enzymatic label, can catalyze a detectable chemical change of a substrate compound or composition.
  • the term is intended to encompass direct labeling of a probe or antibody by coupling (ie, physically linking) a detectable substance to the probe or antibody and indirect labeling of a probe or antibody by reaction with another reagent that is directly labeled.
  • “Individual” or “subject” includes mammals. Mammals include, but are not limited to, domestic animals (eg, cattle, sheep, cats, dogs, and horses), primates (eg, humans and non-human primates such as monkeys), rabbits, and rodents (eg, , mice and rats). In some embodiments, the individual or subject is a human.
  • an “isolated” antibody is one that has been separated from components of its natural environment.
  • the antibody is purified to greater than 95% or 99% purity, such as by, eg, electrophoresis (eg, SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (eg, ion exchange or reversed phase) HPLC) determined.
  • electrophoresis eg, SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
  • chromatography eg, ion exchange or reversed phase
  • isolated nucleic acid encoding an anti-CLDN18.2xCD3 bispecific antibody or fragment thereof refers to one or more nucleic acid molecules that encode an antibody heavy or light chain (or fragment thereof, eg, heavy chain variable region or light chain variable region) regions), including such nucleic acid molecules in a single vector or in separate vectors, as well as such nucleic acid molecules present at one or more locations in a host cell.
  • the sequences are aligned for optimal comparison purposes (e.g., between the first and second amino acid sequences or nucleic acid sequences for optimal alignment. Gaps are introduced in one or both or non-homologous sequences can be discarded for comparison purposes).
  • the length of the reference sequences aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60% and even more preferably at least 70%, 80% , 90%, 100% of the reference sequence length.
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide at the corresponding position in the second sequence, then the molecules are identical at that position.
  • Sequence comparisons and calculation of percent identity between two sequences can be accomplished using mathematical algorithms.
  • the Needlema and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm (at http://www.gcg.com) is used that has been integrated into the GAP program of the GCG software package available), using the Blossum 62 matrix or the PAM250 matrix and gap weights 16, 14, 12, 10, 8, 6, or 4 and length weights 1, 2, 3, 4, 5, or 6, to determine the distance between two amino acid sequences percent identity.
  • the GAP program in the GCG software package (available at http://www.gcg.com) is used, using the NWSgapdna.CMP matrix and gap weights 40, 50, 60, 70 or 80 and A length weight of 1, 2, 3, 4, 5, or 6 determines the percent identity between two nucleotide sequences.
  • a particularly preferred set of parameters is the Blossum 62 scoring matrix with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5. It is also possible to use the PAM120 weighted remainder table, gap length penalty of 12, gap penalty of 4), using the E. Meyers and W.
  • nucleic acid sequences and protein sequences described herein can be further used as "query sequences" to perform searches against public databases, eg, to identify other family member sequences or related sequences.
  • hybridizes under stringent conditions eg, under conditions of low stringency, moderate stringency, high stringency, or very high stringency
  • stringent conditions eg, under conditions of low stringency, moderate stringency, high stringency, or very high stringency
  • Guidance for performing hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6, incorporated by reference. Aqueous and non-aqueous methods are described in the references and either method can be used.
  • the preferred hybridization conditions referred to herein are as follows: 1) Low stringency hybridization conditions are at about 45°C in 6X sodium chloride/sodium citrate (SSC) followed by at least 50°C (for low stringency conditions, you can Increase the temperature of the wash to 55°C) twice in 0.2X SSC, 0.1% SDS; 2) Moderate stringency hybridization conditions are about 45°C in 6X SSC followed by 0.2X SSC, 0.1% SDS at 60°C 3) high stringency hybridization conditions are one or more washes in 6X SSC at about 45°C followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C; and preferably 4) extremely high Stringent hybridization conditions were one or more washes in 0.5M sodium phosphate, 7% SDS at 65°C followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C. Very high stringency conditions (4) are the preferred conditions and the one that should be used unless otherwise specified.
  • anti-tumor effect refers to a biological effect that can be exhibited by a variety of means including, but not limited to, for example, reduction in tumor volume, reduction in tumor cell number, reduction in tumor cell proliferation, or reduction in tumor cell survival.
  • tumor and cancer are used interchangeably herein to encompass both solid tumors and hematological tumors.
  • cancers suitable for treatment by the antibodies of the invention include gastric cancer, pancreatic cancer, or gastroesophageal junction cancer, including metastatic forms of those cancers.
  • tumor refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
  • cancer refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
  • cancer refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
  • pharmaceutical adjuvant refers to a diluent, adjuvant (eg, Freund's adjuvant (complete and incomplete)), excipient, carrier or stabilizer, etc., with which the active substance is administered.
  • composition refers to a composition that is in a form that allows the biological activity of the active ingredients contained therein to be effective and does not contain additional ingredients.
  • non-fixed combination means that the active ingredients (eg, (i) an anti-CLDN18.2xCD3 bispecific antibody or fragment thereof of the invention, and (ii) other therapeutic agents) are contemporaneously, without specific time constraints, as separate entities or administered to the patient sequentially at the same or different time intervals, wherein such administration provides prophylactically or therapeutically effective levels of the two or more active agents in the patient.
  • the anti-CLDN18.2xCD3 bispecific antibodies or fragments thereof of the invention and other therapeutic agents of the invention used in pharmaceutical combinations are administered at levels no greater than when they are used alone.
  • the term "fixed combination" means that two or more active agents are administered to a patient simultaneously in the form of a single entity.
  • the doses and/or time intervals of the two or more active agents are preferably selected so that the combined use of the parts produces a greater effect in the treatment of a disease or condition than either component alone can achieve.
  • the ingredients may each be in separate formulations, which may be the same or different.
  • combination therapy refers to the administration of two or more therapeutic agents or treatment modalities (eg, radiation therapy or surgery) to treat the diseases described herein.
  • administration includes co-administration of the therapeutic agents in a substantially simultaneous manner, eg, in a single capsule having a fixed ratio of active ingredients.
  • administration includes co-administration of the individual active ingredients in multiple or separate containers such as tablets, capsules, powders and liquids. Powders and/or liquids can be reconstituted or diluted to the desired dose prior to administration.
  • such administration also includes the sequential use of each type of therapeutic agent at approximately the same time or at different times. In either case, the treatment regimen will provide the beneficial effect of the drug combination in the treatment of the disorders or conditions described herein.
  • treating refers to slowing, interrupting, retarding, alleviating, stopping, reducing, or reversing the progression or severity of an existing symptom, disorder, condition, or disease.
  • prevention includes the inhibition of the occurrence or progression of a disease or disorder or symptoms of a particular disease or disorder.
  • subjects with a family history of cancer are candidates for preventive regimens.
  • prevention refers to the administration of a drug prior to the onset of signs or symptoms of cancer, particularly in subjects at risk of cancer.
  • vector refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked.
  • the term includes vectors that are self-replicating nucleic acid structures as well as vectors that are incorporated into the genome of the host cell into which they have been introduced. Some vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors”.
  • a "subject/patient/individual sample” refers to a collection of cells or fluids obtained from a patient or subject.
  • the source of a tissue or cell sample can be solid tissue like from a fresh, frozen and/or preserved organ or tissue sample or biopsy or biopsy; blood or any blood component; bodily fluids such as cerebrospinal fluid, amniotic fluid (amniotic fluid); ), peritoneal fluid (ascites), or interstitial fluid; cells from any time of pregnancy or development of the subject.
  • Tissue samples may contain compounds that are not naturally mixed with tissue in nature, such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, and the like.
  • the anti-CLDN18.2xCD3 bispecific antibodies of the invention bind CLDN18.2 (e.g., human CLDN18.2) with high affinity.
  • the antibodies of the invention specifically bind CLDN18.2 (eg, human CLDN18.2), but not CLDN18.1 (eg, human CLDN18.1).
  • the antibodies of the invention or antigen-binding fragments thereof have higher binding affinity to human CLDN18.2 than known CLDN18.2 antibodies, such as the Zolbetuximab (Zmab for short) antibody.
  • the anti-CLDN18.2 x CD3 bispecific antibodies of the invention bind CD3 (eg, human CD3 or cynomolgus CD3) with a desired affinity (eg, lower).
  • the antibodies of the invention are capable of binding both human CD3 and cynomolgus CD3.
  • the affinity of the antibody is determined by biofilm interferometry or surface plasmon resonance.
  • the anti-CLDN18.2 x CD3 bispecific antibodies of the invention are capable of binding CLDN18.2 on the surface of tumor cells, as well as CD3 on the surface of effector cells. In some embodiments, the binding is detected using flow cytometry.
  • the antibodies of the invention are capable of specifically killing tumor cells, eg, tumor cells expressing CLDN18.2. In some embodiments, the antibodies of the invention are capable of mediating the release of cytokines, such as IL-2, TNF ⁇ and/or IFNgamma. In some embodiments, the antibodies of the invention are capable of activating effector cells, eg, T cells.
  • the effector cells are T cells, eg, T lymphocytes, eg, CD4+ T cells or CD8+ T cells.
  • the antibodies or antigen-binding fragments thereof of the invention can be used to treat cancer.
  • the antibody or antigen-binding fragment thereof of the present invention can effectively inhibit tumor growth, and the tumor inhibition rate is greater than or equal to about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, even 100%.
  • the bispecific antibodies of the invention comprise a first antigen binding domain and a second antigen binding domain, wherein the first antigen binding domain specifically binds CLDN18.2 and the second antigen binding domain specifically binds CLDN18.2 Binds CD3.
  • the first antigen binding domain comprises three complementarity determining regions (A1-HCDR) from the heavy chain variable region, A1-HCDR1, A1-HCDR2 and A1-HCDR3.
  • A1-HCDR complementarity determining regions
  • the first antigen binding domain comprises three complementarity determining regions (A1-LCDR) from the light chain variable region, A1-LCDR1, A1-LCDR2 and A1-LCDR3.
  • A1-LCDR complementarity determining regions
  • the first antigen binding domain comprises three complementarity determining regions (A1-HCDR) from the heavy chain variable region and three complementarity determining regions (A1-LCDR) from the light chain variable region.
  • the first antigen binding domain comprises a heavy chain variable region (A1-VH). In some aspects, the first antigen binding domain comprises a light chain variable region (A1-VL). In some aspects, the first antigen binding domain comprises a heavy chain variable region and a light chain variable region. In some embodiments, the heavy chain variable region comprises three complementarity determining regions (A1-HCDR) from the heavy chain variable region, HCDR1, HCDR2 and HCDR3. In some embodiments, the light chain variable region comprises three complementarity determining regions (A1-LCDR) from the light chain variable region, LCDR1, LCDR2 and LCDR3.
  • A1-VH A1-VH
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 4; or
  • amino acid changes comprising 1 or more (preferably no more than 10, more preferably no more than 5, 4, 3, 2, 1) amino acid changes (preferably The amino acid sequence of amino acid substitutions, more preferably conservative substitutions of amino acids, consists of the amino acid sequence, preferably, the amino acid changes do not occur in the CDR regions.
  • A1-VL A1-VL
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 9; or
  • amino acid changes (preferably no more than 1) compared to the amino acid sequence selected from SEQ ID NO: 9
  • amino acid sequence of amino acid substitutions more preferably conservative substitutions of amino acids, consists of the amino acid sequence, preferably, the amino acid changes do not occur in the CDR regions.
  • the three complementarity determining regions (A1-HCDR) from A1-VH of the invention are: A1-HCDR1, A1-HCDR2 and A1-HCDR3 are:
  • the three complementarity determining regions (A1-LCDR) from A1-VL of the invention are: A1-LCDR1, A1-LCDR2 and A1-LCDR3 are:
  • A1-HCDR1 comprises, or consists of, the amino acid sequence of SEQ ID NO:1, or A1-HCDR1 comprises one, two, or three amino acid sequences compared to the amino acid sequence of SEQ ID NO:1 An altered (preferably amino acid substitution, preferably conservative substitution) amino acid sequence.
  • A1-HCDR2 comprises or consists of the amino acid sequence of SEQ ID NO:2, or A1-HCDR2 comprises one, two or three amino acid sequences compared to the amino acid sequence of SEQ ID NO:2 An altered (preferably amino acid substitution, preferably conservative substitution) amino acid sequence.
  • A1-HCDR3 comprises or consists of the amino acid sequence of SEQ ID NO:3, or A1-HCDR3 comprises one, two or three amino acid sequences compared to the amino acid sequence of SEQ ID NO:3 An altered (preferably amino acid substitution, preferably conservative substitution) amino acid sequence.
  • A1-LCDR1 comprises or consists of the amino acid sequence of SEQ ID NO:6, or A1-LCDR1 comprises one, two or three amino acid sequences compared to the amino acid sequence of SEQ ID NO:6 An altered (preferably amino acid substitution, preferably conservative substitution) amino acid sequence.
  • A1-LCDR2 comprises or consists of the amino acid sequence of SEQ ID NO:7, or A1-LCDR2 comprises one, two or three amino acid sequences compared to the amino acid sequence of SEQ ID NO:7 An altered (preferably amino acid substitution, preferably conservative substitution) amino acid sequence.
  • A1-LCDR3 comprises or consists of the amino acid sequence of SEQ ID NO:8, or A1-LCDR3 comprises one, two or three amino acid sequences compared to the amino acid sequence of SEQ ID NO:8 An altered (preferably amino acid substitution, preferably conservative substitution) amino acid sequence.
  • the second antigen binding domain comprises three complementarity determining regions (A2-HCDR) from the heavy chain variable region, A2-HCDR1, A2-HCDR2 and A2-HCDR3.
  • A2-HCDR complementarity determining regions
  • the second antigen binding domain comprises three complementarity determining regions (A2-LCDR) from the light chain variable region, A2-LCDR1, A2-LCDR2 and A2-LCDR3.
  • A2-LCDR complementarity determining regions
  • the second antigen binding domain comprises three complementarity determining regions (A2-HCDR) from the heavy chain variable region and three complementarity determining regions (A2-LCDR) from the light chain variable region.
  • the second antigen binding domain comprises a heavy chain variable region (A2-VH). In some aspects, the second antigen binding domain comprises a light chain variable region (A2-VL). In some aspects, the second antigen binding domain comprises a heavy chain variable region and a light chain variable region. In some embodiments, the heavy chain variable region comprises three complementarity determining regions (A2-HCDR) from the heavy chain variable region, HCDR1, HCDR2 and HCDR3. In some embodiments, the light chain variable region comprises three complementarity determining regions (A2-LCDR) from the light chain variable region, LCDR1, LCDR2 and LCDR3.
  • A2-VH A2-VH
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 22, 30 or 32; or
  • amino acid sequence of amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions) consists of the amino acid sequence, preferably, the amino acid changes do not occur in the CDR regions.
  • A2-VL A2-VL
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 27; or
  • amino acid changes (preferably) compared to the amino acid sequence selected from SEQ ID NO: 27
  • amino acid sequence of amino acid substitutions more preferably conservative substitutions of amino acids, consists of the amino acid sequence, preferably, the amino acid changes do not occur in the CDR regions.
  • the three complementarity determining regions (A2-HCDR) from A2-VH of the invention are: A2-HCDR1, A2-HCDR2 and A2-HCDR3 are:
  • the three complementarity determining regions (A2-LCDR) from A2-VL, A2-LCDR1, A2-LCDR2 and A2-LCDR3 of the invention are
  • the A2-HCDR1 comprises or consists of the amino acid sequence of SEQ ID NO: 19, or the A2-HCDR1 comprises one, two or three amino acid sequences compared to the amino acid sequence of SEQ ID NO: 19 An altered (preferably amino acid substitution, preferably conservative substitution) amino acid sequence.
  • the A2-HCDR2 comprises or consists of the amino acid sequence of SEQ ID NO: 20 or 31, or the A2-HCDR2 comprises, compared to the amino acid sequence of SEQ ID NO: 20 or 31, has one, Two or three altered (preferably amino acid substitutions, preferably conservative substitutions) amino acid sequences.
  • the A2-HCDR3 comprises or consists of the amino acid sequence of SEQ ID NO: 21 or 29, or the A2-HCDR3 comprises, compared to the amino acid sequence of SEQ ID NO: 21 or 29, has one, Two or three altered (preferably amino acid substitutions, preferably conservative substitutions) amino acid sequences.
  • A2-LCDR1 comprises or consists of the amino acid sequence of SEQ ID NO:24, or A2-LCDR1 comprises one, two or three amino acids compared to the amino acid sequence of SEQ ID NO:24 An altered (preferably amino acid substitution, preferably conservative substitution) amino acid sequence.
  • A2-LCDR2 comprises or consists of the amino acid sequence of SEQ ID NO:25, or A2-LCDR2 comprises one, two or three amino acid sequences compared to the amino acid sequence of SEQ ID NO:25 An altered (preferably amino acid substitution, preferably conservative substitution) amino acid sequence.
  • A2-LCDR3 comprises or consists of the amino acid sequence of SEQ ID NO:26, or A2-LCDR3 comprises one, two or three amino acid sequences compared to the amino acid sequence of SEQ ID NO:26 An altered (preferably amino acid substitution, preferably conservative substitution) amino acid sequence.
  • the bispecific antibodies of the invention further comprise a heavy chain constant region. In some embodiments, the bispecific antibodies of the invention further comprise a light chain constant region. In some embodiments, the bispecific antibodies of the invention further comprise a heavy chain constant region and a light chain constant region. In some embodiments, the bispecific antibodies of the invention comprise 2 heavy chain constant regions, wherein one heavy chain constant region A1-HC is linked to the heavy chain variable region A1-VH of the first antigenic domain to form a connection with CDLN18. The heavy chain of the 2 binding moiety, and the other heavy chain constant region A2-HC is linked to the heavy chain variable region A2-VH of the second antigen binding domain to form the heavy chain of the CD3 binding moiety.
  • the bispecific antibodies of the present invention comprise 2 light chain constant regions, wherein one light chain constant region A1-LC is linked to the light chain variable region A1-VL of the first antigenic domain to form CLDN18. 2 is the light chain of the binding moiety, and the other light chain constant region A2-LC is linked to the light chain variable region A2-VL of the second antigen binding domain to form the light chain of the CD3 binding moiety.
  • the bispecific antibody of the invention comprises A1-HC, A1-LC, A2-HC and A2-LC.
  • A1-HC can be the same or different from A2-HC.
  • A1-LC can be the same or different from A2-LC.
  • A1-HC is different from A2-HC
  • A1-LC is different from A2-LC.
  • the heavy chain constant region HC of the invention is the heavy chain constant region of IgG1, IgG2, IgG3 or IgG4, preferably the heavy chain constant region of IgG1, such as a wild-type IgG1 heavy chain constant region or a mutated IgG1 heavy chain constant region Chain constant region (eg IgG1 LALA).
  • the antibody light chain constant region LC of the invention is a lambda or Kappa light chain constant region.
  • the heavy chain constant region HC of the invention is a heavy chain constant region HC of the invention.
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 5 or 23; or
  • amino acid sequence of amino acid changes (preferably amino acid substitutions, more preferably conservative substitutions of amino acids) of or consisting of said amino acid sequences.
  • the heavy chain constant region HC of the invention is a heavy chain constant region HC of the invention.
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 33 or 34; or
  • amino acid sequence of amino acid changes (preferably amino acid substitutions, more preferably conservative substitutions of amino acids) of or consisting of said amino acid sequences.
  • the antibody light chain constant region LC of the invention is provided.
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 10 or 28; or
  • amino acid sequence of amino acid changes (preferably amino acid substitutions, more preferably conservative substitutions of amino acids) of or consisting of said amino acid sequences.
  • the bispecific antibodies of the invention comprise a first antigen binding domain and a second antigen binding domain, wherein
  • the first antigen-binding domain specifically binds CLDN18.2, the second antigen-binding domain specifically binds CD3, wherein the first antigen-binding domain comprises the three contained in A1-VH as shown in SEQ ID NO:4 complementarity determining regions A1-HCDR1, A1-HCDR2 and A1-HCDR3, and three complementarity determining regions A1-LCDR1, A1-LCDR2 and A1-LCDR3 contained in VL as shown in SEQ ID NO:9;
  • the second antigen binding domain comprises the three complementarity determining regions A2-HCDR1, A2-HCDR2 and A2-HCDR3 contained in A2-VH as set forth in SEQ ID NO: 22, 30 or 32, and as set forth in SEQ ID NO: The three complementarity determining regions A2-LCDR1, A2-LCDR2 and A2-LCDR3 contained in A2-VL shown at 27.
  • the bispecific antibodies of the invention comprise a first antigen binding domain and a second antigen binding domain, wherein the first antigen binding domain specifically binds CLDN18.2 and the second antigen binds domain specifically binds CD3, where
  • the first antigen binding domain comprises A1-HCDR1, A1-HCDR2, A1-HCDR3, respectively, as shown in the following amino acid sequences: SEQ ID NOs: 1, 2, and 3, and A1-LCDR1, A1-LCDR1, A1-LCDR2 and A1-LCDR3: SEQ ID NOs: 6, 7 and 8; and
  • the second antigen binding domain comprises
  • the bispecific antibodies of the invention comprise a first antigen binding domain and a second antigen binding domain, wherein the first antigen binding domain specifically binds CLDN18.2 and the second antigen binds domain specifically binds CD3, where
  • the first antigen binding domain comprises or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the amino acid sequence set forth in SEQ ID NO:4
  • the second antigen binding domain comprises the amino acid sequence set forth in SEQ ID NO: 22, 30 or 32 or an amino acid sequence having at least 90% identity thereto or A2-VH consisting of said amino acid sequence, and comprises SEQ ID NO: 27 the amino acid sequence shown in A2-VL.
  • the bispecific antibodies of the invention are bispecific antibodies of IgG-like structure, ie they comprise heavy and light chains that bind to CLDN18.2, and that bind to CD3 heavy and light chains.
  • the sequence of Knob-into-Hole is present in the CH3 regions of both heavy chains (Shane Atwell et al., Journal of Molecular Biology, 1997; A. Margaret Merchant et al., Nature Biotechnology, 1998), thus forming a knob-hole structure .
  • the structures of bispecific antibodies of the invention are shown in FIG. 8 .
  • the heavy chain of the CLDN18.2 binding moiety is the heavy chain of the CLDN18.2 binding moiety
  • amino acid sequence comprising 1 or more (preferably no more than 20 or 10, more preferably no more than 5, 4, 3, 2, 1) amino acids compared to the amino acid sequence selected from the group consisting of SEQ ID NO: 37
  • the amino acid sequence that is altered is or consists of said amino acid sequence.
  • the light chain of the binding moiety to CLDN18.2 is the light chain of the binding moiety to CLDN18.2
  • amino acid sequence comprising 1 or more (preferably no more than 20 or 10, more preferably no more than 5, 4, 3, 2, 1) amino acids compared to the amino acid sequence selected from the group consisting of SEQ ID NO: 38
  • the amino acid sequence that is altered is or consists of said amino acid sequence.
  • the heavy chain of the CD3 binding moiety is the heavy chain of the CD3 binding moiety
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 39, 41 or 42; or
  • amino acid sequence of amino acid changes preferably amino acid substitutions, more preferably conservative substitutions of amino acids or consisting of said amino acid sequences.
  • the light chain of the CD3 binding moiety is the light chain of the CD3 binding moiety
  • (ii) comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 40; or
  • amino acid sequence comprising 1 or more (preferably no more than 20 or 10, more preferably no more than 5, 4, 3, 2, 1) amino acids compared to the amino acid sequence selected from the group consisting of SEQ ID NO: 40
  • the amino acid sequence that is altered is or consists of said amino acid sequence.
  • the amino acid changes described herein include amino acid substitutions, insertions or deletions.
  • the amino acid changes described herein are amino acid substitutions, preferably conservative substitutions.
  • the amino acid changes described herein occur in regions outside the CDRs (eg, in FRs). More preferably, the amino acid changes described in the present invention occur in regions outside the variable region of the heavy chain and/or outside the variable region of the light chain. In some embodiments, the amino acid changes described herein occur in the Fc region of the heavy chain constant region of an antibody, and in preferred embodiments, the amino acid changes in the Fc region impair or delete the ADCC and/or ADCC of the antibody CDC role.
  • substitutions are conservative substitutions.
  • Conservative substitutions refer to the substitution of one amino acid with another amino acid within the same class, e.g., substitution of an acidic amino acid with another acidic amino acid, substitution of a basic amino acid with another basic amino acid, or substitution of a neutral amino acid with another neutral amino acid replacement. Exemplary permutations are shown in the following table:
  • the substitutions occur in the CDR regions of the antibody.
  • the variant obtained has a modification (eg, improvement) in certain biological properties (eg, increased affinity) relative to the parent antibody and/or will have certain biological properties that are substantially retained of the parent antibody.
  • exemplary substitutional variants are affinity matured antibodies.
  • one or more amino acid modifications can be introduced into the Fc region of the antibodies provided herein, thereby generating Fc region variants, to alter one or more functional properties of the antibody, such as serum half-life, serum half-life, Complement fixation, complement dependent cytotoxicity, Fc receptor binding and/or antibody dependent cytotoxicity.
  • Fc region variants can include human Fc region sequences (eg, human IgGl, IgG2, IgG3, or IgG4 Fc regions) comprising amino acid changes (eg, substitutions) at one or more amino acid positions.
  • cysteine-engineered antibodies eg, "thioMAbs”
  • one or more residues of the antibody are replaced with cysteine residues.
  • the antibodies provided herein can be further modified to contain other non-proteinaceous moieties known in the art and readily available.
  • Moieties suitable for antibody derivatization include, but are not limited to, water-soluble polymers.
  • Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol/propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl -1,3-dioxane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers), and dextran or poly(n-ethylene pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide copolymers, polyoxyethylated polyols (eg, glycerol), polyvinyl alcohol,
  • the first antigen binding domain that specifically binds to CLDN18.2, or the combination of heavy and light chains is fully human
  • the second antigen binding domain that binds CD3 The antigen binding domain or heavy and light chain combination is humanized.
  • the present invention provides nucleic acids encoding variable regions or heavy or light chains of any of the above bispecific antibodies.
  • a vector comprising the nucleic acid is provided.
  • the vector is an expression vector such as pcDNA3.1.
  • a host cell comprising the nucleic acid or the vector is provided.
  • the host cell is eukaryotic.
  • the host cell is selected from yeast cells, mammalian cells (eg, CHO cells (eg, CHO-S) or 293 cells (eg, 293F or HEK293 cells)), or other cells suitable for the production of antibodies or fragments thereof.
  • the host cell is prokaryotic.
  • a nucleic acid of the invention may comprise a nucleic acid encoding the amino acid sequence of the light chain variable region and/or heavy chain variable region of an antibody, or a nucleic acid encoding the amino acid sequence of the light chain and/or heavy chain of an antibody.
  • the nucleic acid of the present invention comprises a nucleic acid encoding an amino acid sequence selected from any one of SEQ ID NO:4, 9, 22, 27, 30, 32, 37-42, or encoding an amino acid sequence selected from SEQ ID NO:4 , 9, 22, 27, 30, 32, 37-42
  • nucleic acids that hybridize under stringent conditions or have one or more substitutions (e.g. conservative substitutions), deletions or insertions with a nucleic acid comprising an encoding selected from the group consisting of SEQ ID NO:4,
  • the amino acid sequence set forth in any one of -42 has at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity of amino acids Sequence of nucleic acid sequence of nucleic acid.
  • one or more vectors are provided comprising the nucleic acid.
  • the vector is an expression vector, such as a eukaryotic expression vector.
  • Vectors include, but are not limited to, viruses, plasmids, cosmids, lambda phage, or yeast artificial chromosomes (YACs).
  • YACs yeast artificial chromosomes
  • the vector is pcDNA3.1.
  • a host cell comprising the vector.
  • Suitable host cells for cloning or expressing antibody-encoding vectors include prokaryotic or eukaryotic cells described herein.
  • antibodies can be produced in bacteria, particularly when glycosylation and Fc effector functions are not required. After expression, the antibody can be isolated from the bacterial cell paste in the soluble fraction and can be further purified.
  • the host cell is eukaryotic.
  • the host cell is selected from yeast cells, mammalian cells, or other cells suitable for the production of antibodies or fragments thereof.
  • eukaryotic microorganisms such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors.
  • fungal and yeast strains in which the glycosylation pathway has been "humanized” result in antibodies with partially or fully human glycosylation patterns.
  • Host cells suitable for expression of glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Vertebrate cells can also be used as hosts.
  • mammalian cell lines engineered for growth in suspension can be used.
  • useful mammalian host cell lines are the monkey kidney CV1 line (COS-7) transformed with SV40; the human embryonic kidney line (HEK293, 293F or 293T cells) and the like.
  • Other useful mammalian host cell lines include Chinese Hamster Ovary (CHO) cells, including DHFR-CHO cells, CHO-S cells, ExpiCHO, etc.; and myeloma cell lines such as Y0, NSO, and Sp2/0. Suitable mammalian host cell lines for the production of antibodies are known in the art.
  • a method of making an antibody molecule of the invention comprises, under conditions suitable for expression of the antibody, culturing a compound encoding the antibody (eg, any polypeptide chain and/or polypeptide chains) A nucleic acid or a host cell comprising an expression vector of the nucleic acid, as provided above, and optionally recovering the antibody from the host cell (or host cell culture medium).
  • a compound encoding the antibody eg, any polypeptide chain and/or polypeptide chains
  • a nucleic acid or a host cell comprising an expression vector of the nucleic acid, as provided above, and optionally recovering the antibody from the host cell (or host cell culture medium).
  • nucleic acid encoding the antibody eg, the antibodies described above, eg, any polypeptide chain and/or polypeptide chains
  • nucleic acids are readily isolated and sequenced using conventional procedures (eg, by using oligonucleotide probes capable of binding specifically to genes encoding antibody heavy and light chains).
  • Antibody molecules prepared as described herein can be purified by known prior art techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like.
  • the actual conditions used to purify a particular protein will also depend on factors such as net charge, hydrophobicity, hydrophilicity, etc., and these will be apparent to those skilled in the art.
  • the purity of the antibody molecules of the invention can be determined by any of a variety of well-known analytical methods, including size exclusion chromatography, gel electrophoresis, high performance liquid chromatography, and the like.
  • the antibodies provided herein can be identified, screened, or characterized for their physical/chemical properties and/or biological activity by a variety of assays known in the art.
  • the antibodies of the invention are tested for their antigen-binding activity, eg, by known methods such as ELISA, Western blotting, and the like. Binding to CLDN18.2 and/or CD3 can be determined using methods known in the art, exemplary methods are disclosed herein. In some embodiments, radioimmunoassay (RIA) or biofilm thin layer interferometry or MSD assay or surface plasmon resonance (SPR) or flow cytometry measurement is used.
  • RIA radioimmunoassay
  • MSD assay or surface plasmon resonance (SPR) or flow cytometry measurement
  • competition assays can be used to identify antibodies that compete with any of the bispecific antibodies disclosed herein for binding to CLDN18.2 and/or CD3.
  • competing antibodies bind to the same or overlapping epitopes (eg, linear or conformational epitopes) as the bispecific antibodies disclosed herein.
  • the invention also provides assays for identifying biologically active antibodies.
  • Biological activities may include, for example, binding to CLDN18.2 and/or CD3 (eg, binding to human CLDN18.2 and/or CD3), binding to cells expressing CLDN18.2 and/or CD3, activation of T cells, The secretion and stimulation of factors, the inhibition and killing of tumor cells, etc.
  • Antibodies having such biological activities in vivo and/or in vitro are also provided.
  • antibodies of the invention are tested for such biological activities.
  • Cells for use in any of the above in vitro assays include cell lines that naturally express CLDN18.2 and/or CD3 or are engineered to express or overexpress CLDN18.2 and/or CD3. Such cells also include cell lines transfected with DNA encoding CLDN18.2 and/or CD3 expressing and not normally expressing CLDN18.2 and/or CD3. In some embodiments, such cells are gastric cancer cells or pancreatic cancer cells. In some embodiments, the cells are CHO cells expressing CLDN18.2. In some embodiments, the cells are cell lines NUGC-4, KATO III and DAN-G cell lines, eg, KATO III and DAN-G cell lines overexpressing CLDN18.2. In some embodiments, such cells are T cells, eg, human T lymphocytes, eg, Jurkat cells.
  • the present invention provides compositions comprising any of the antibodies described herein, preferably the compositions are pharmaceutical compositions.
  • the composition further comprises pharmaceutical excipients.
  • a composition eg, a pharmaceutical composition, comprises an antibody or fragment thereof of the invention in combination with one or more other therapeutic agents.
  • compositions comprising the bispecific antibodies of the present invention or compositions thereof (including pharmaceutical compositions). These compositions may also contain suitable pharmaceutical excipients, such as pharmaceutical carriers, pharmaceutical excipients, including buffers, known in the art.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • compositions of the present invention may be in a variety of forms.
  • forms include, for example, liquid, semisolid, and solid dosage forms, such as liquid solutions (eg, injectable solutions and infusible solutions), powders or suspensions, liposomes, and suppositories.
  • liquid solutions eg, injectable solutions and infusible solutions
  • powders or suspensions e.g., liposomes, and suppositories.
  • liposomes e.g., liposomes, and suppositories.
  • suppositories e.g., suppositories.
  • the preferred form depends on the intended mode of administration and therapeutic use.
  • a medicament comprising an antibody described herein can be prepared by mixing an antibody of the invention of the desired purity with one or more optional pharmaceutical excipients, preferably in the form of a lyophilized formulation or an aqueous solution.
  • compositions or formulations of the present invention may also contain more than one active ingredient required for the particular indication being treated, preferably those having complementary activities that do not adversely affect each other.
  • active ingredient e.g., chemotherapeutic agents, angiogenesis inhibitors, cytokines, cytotoxic agents, other antibodies, small molecule drugs, or immunomodulatory agents (eg, immune checkpoint inhibitors or agonists), and the like.
  • the active ingredients are suitably combined in amounts effective for the intended use.
  • sustained release formulations can be prepared. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers containing antibodies in the form of shaped articles such as films or microcapsules.
  • the invention also provides a pharmaceutical combination or pharmaceutical combination product comprising an antibody of the invention, and one or more other therapeutic agents (eg, therapeutic agents, including chemotherapeutic agents, angiogenesis inhibitors, cytokines , cytotoxic agents, other antibodies, small molecule drugs, or immunomodulatory agents (eg, immune checkpoint inhibitors or agonists, etc.).
  • therapeutic agents including chemotherapeutic agents, angiogenesis inhibitors, cytokines , cytotoxic agents, other antibodies, small molecule drugs, or immunomodulatory agents (eg, immune checkpoint inhibitors or agonists, etc.).
  • Another object of the present invention is to provide a kit comprising the pharmaceutical combination of the present invention, preferably the kit is in the form of a pharmaceutical dosage unit. Dosage units can thus be provided according to the dosing regimen or the interval between drug administrations.
  • kit of parts of the present invention contains in the same package:
  • One aspect of the present invention provides a method of preventing or treating a tumor (eg, cancer) in a subject, comprising administering to the subject an effective amount of an anti-CLDN18.2 x CD3 bispecific antibody or fragment thereof (preferably antigen-binding fragment), pharmaceutical composition, pharmaceutical combination or kit.
  • a tumor eg, cancer
  • an anti-CLDN18.2 x CD3 bispecific antibody or fragment thereof preferably antigen-binding fragment
  • the tumor (eg, cancer) patient has (eg, elevated levels, eg, nucleic acid or protein levels) CLDN18.2.
  • the tumor eg, cancer
  • the tumor includes solid and hematological tumors and metastatic lesions.
  • examples of solid tumors include malignant tumors. Cancer can be in early, intermediate or advanced stages or metastatic.
  • the tumor therapy will benefit from inhibition of CLDN18.2 at the nucleic acid or protein level.
  • the antibodies of the invention are capable of killing tumor cells, and/or inhibiting tumor cell proliferation, eg, CLDN18.2 expressing tumor cells, eg, gastric cancer cells or pancreatic cancer cells.
  • the anti-CLDN18.2 x CD3 bispecific antibodies of the invention are capable of activating T cells.
  • the antibodies of the present invention are suitable for use in the prevention or treatment of any tumor or cancer in which an effector mechanism of cytotoxic T cells is required, or any tumor or cancer in which T cell recruitment is required.
  • the tumor is tumor immune escape.
  • the tumor is cancer, such as gastric cancer or pancreatic cancer
  • the subject can be a mammal, eg, a primate, preferably a higher primate, eg, a human (eg, suffering from a disease described herein). disease or an individual at risk of having the disease described herein).
  • the subject has or is at risk of having a disease described herein (eg, cancer).
  • the subject receives or has received other treatments, such as chemotherapy treatment and/or radiation therapy.
  • the subject has previously received or is receiving immunotherapy.
  • the present invention provides the use of an antibody molecule or a pharmaceutical composition or pharmaceutical combination or kit in the manufacture or manufacture of a medicament for the use described herein, eg for the prevention or treatment of a related reference mentioned herein disease or condition.
  • the antibody molecule or pharmaceutical composition or pharmaceutical combination or kit of the invention delays the onset of the disorder and/or symptoms associated with the disorder.
  • the antibody molecules or pharmaceutical compositions of the invention can also be administered in combination with one or more other therapies, eg, therapeutic modalities and/or other therapeutic agents, for the uses described herein, eg, for prophylaxis and /or to treat a related disease or condition mentioned herein.
  • therapies eg, therapeutic modalities and/or other therapeutic agents, for the uses described herein, eg, for prophylaxis and /or to treat a related disease or condition mentioned herein.
  • the treatment modality includes surgery; radiation therapy, localized or focused radiation, and the like.
  • the therapeutic agent is selected from chemotherapeutic agents, angiogenesis inhibitors, cytokines, cytotoxic agents, other antibodies, small molecule drugs, or immunomodulatory agents (eg, immune checkpoint inhibitors or agonists).
  • immunomodulatory agents include immunosuppressive or anti-inflammatory agents.
  • the immunomodulatory agent further includes an immune checkpoint inhibitor or agonist.
  • Exemplary other antibodies include antibodies that specifically bind immune checkpoints.
  • the antibody combinations described herein can be administered separately, e.g., as separate antibodies.
  • Such combination therapy encompasses combined administration (eg, two or more therapeutic agents are contained in the same formulation or separate formulations), and separate administration, in which case the additional therapeutic agents and/or agents may be administered Administration of the antibodies of the invention occurs before, simultaneously, and/or after.
  • the route of administration of the pharmaceutical composition is according to known methods, eg, orally, by intravenous injection, intraperitoneal, intracerebral (intraparenchymal), intracerebroventricular, intramuscular, intraocular, intraarterial, intraportal or intralesional Routes; via sustained release systems or via implanted devices.
  • the compositions can be administered by bolus injection or by continuous infusion or by implanted devices.
  • composition may also be administered topically via an implanted membrane, sponge, or another suitable material on which the desired molecule is absorbed or encapsulated.
  • an implanted device when used, the device can be implanted into any suitable tissue or organ, and the desired molecule can be delivered via diffusion, timed-release bolus, or continuous administration.
  • any of the antibodies provided herein can be used to detect the presence of CLDN18.2 in a biological sample.
  • detection includes quantitative or qualitative detection, and exemplary detection methods may involve immunohistochemistry, immunocytochemistry, flow cytometry (eg, FACS), magnetic beads complexed with antibody molecules, ELISA assays methods, PCR-techniques (eg RT-PCR).
  • the biological sample is blood, serum, or other fluid sample of biological origin.
  • the biological sample comprises cells or tissues.
  • the biological sample is from a hyperproliferative or cancerous lesion associated lesion.
  • bispecific antibodies for use in diagnostic or detection methods are provided.
  • a method of detecting the presence of CLDN18.2 in a biological sample comprises detecting the presence of CLDN18.2 protein in a biological sample.
  • the CLDN18.2 is human CLDN18.2.
  • the CD3 is human CD3.
  • the method comprises contacting a biological sample with an antibody as described herein under conditions that allow it to bind to CLDN18.2, and detecting whether a complex is formed between the antibody and CLDN18.2. Formation of the complex indicates the presence of CLDN18.2.
  • the method can be in vitro or in vivo.
  • the antibodies of the invention are used to select subjects suitable for treatment with the bispecific antibodies of the invention, eg, wherein CLDN18.2 is a biomarker for selection of said subjects.
  • the antibodies of the invention can be used to diagnose tumors, eg, cancers, eg, to evaluate (eg, monitor) treatment or progression, diagnosis and/or staging of a disease described herein in an individual.
  • labeled bispecific antibodies are provided.
  • Labels include, but are not limited to, labels or moieties that are detected directly (such as fluorescent labels, chromophore labels, electron-dense labels, chemiluminescent labels, and radioactive labels), and moieties that are detected indirectly, such as enzymes or ligands, for example, through enzymatic reactions or molecular interactions.
  • the sample is obtained prior to treatment with an antibody of the invention. In some embodiments, the sample is obtained prior to other therapy. In some embodiments, the sample is obtained during or after treatment with the other therapy.
  • the sample is formalin-fixed, paraffin-coated (FFPE).
  • FFPE formalin-fixed, paraffin-coated
  • the sample is a biopsy (eg, a core biopsy), a surgical specimen (eg, a specimen from a surgical resection), or a fine needle aspirate.
  • CLDN18.2 is detected prior to treatment, eg, prior to initiation of treatment or prior to a treatment following a treatment interval.
  • a method of treating a disease of the present invention comprising: testing a subject (eg, a sample) (eg, a subject sample) for the presence of CLDN18.2, thereby determining CLDN18.2. 2 values, the CLDN18.2 value is compared to a control value, and if the CLDN18.2 value is greater than the control value, administering to the subject a therapeutically effective amount of the invention, optionally in combination with one or more other therapies Bispecific antibodies thus treat the disease.
  • the kit (Invitrogen, A1369601) was used to construct a cell line stably expressing human Claudin18.2 (abbreviated as CLDN18.2, the same below).
  • CLDN18.2 human Claudin18.2
  • the full-length gene of human CLDN18.2 (UniProt ID: P56856-2) was constructed into the vector pCHO1.0 to form a plasmid, and the constructed plasmids were transferred into CHO- In S cells (Invitrogen, A1369601) and HEK293 cells (Invitrogen, A14527), the transfected cells were subjected to two rounds of pressure screening to obtain cell pools expressing CLDN18.2 respectively.
  • the kit (Invitrogen, A1369601) was used to construct a cell line stably expressing human Claudin18.1 (abbreviated as CLDN18.1, the same below).
  • CLDN18.1 human Claudin18.1
  • the full-length gene of human CLDN18.1 (UniProt ID: P56856-1) was constructed into the vector pCHO1.0 (Invitrogen, A1369601) to form a plasmid, and the constructed plasmid was transferred into CHO-S cells by chemical transfection (Invitrogen, A1369601), the transfected cells were subjected to two rounds of pressurized screening to obtain cell pools expressing CLDN18.1 respectively.
  • the full-length gene of human CLDN18.2 (UniProt ID: P56856-2) was constructed into the vector pWPT-GFP (Addgene, 12255), the GFP sequence was replaced, and the lentiviral packaging vector psPAX2 (Addgene, 12260) and pMD2.G (Addgene, 12259) was co-transfected into HEK293T (ATCC, CRL-3216) cells for virus packaging. The culture supernatants after culturing for 48 hours and 72 hours were collected, and the lentivirus was concentrated using PEG8000.
  • Pancreatic cancer DAN-G cells and gastric cancer KATO III cells were transfected with the concentrated virus, and then the cells expressing CLDN18.2 were sorted by flow cytometry (MoFlo XDP, Beckman Coulter) to obtain stable transfection of CLDN18 .2 tumor cell lines DAN-G-hCLDN18.2 and KATO III-hCLDN18.2.
  • the present invention adopts hybridoma technology to immunize mouse H2L2 fully human antibody transgenic mice (purchased from Harbour BioMed) with the cells (CHO-hCLDN18.2) obtained in Example 1. Then, spleen cells from mice were obtained for electrofusion with myeloma cells. Afterwards, the supernatant was collected and screened by flow cytometry (FACS) to screen out hybridoma cells that specifically express anti-CLDN18.2 antibody, and the secreted antibody did not bind to CLDN18.1. The cells to be detected (HEK293-hCLDN18.2) obtained in Example 1 were counted, diluted to 1 ⁇ 10 6 cells/ml, and 100 ⁇ l/well was added to a U-bottom 96-well plate.
  • FACS flow cytometry
  • the anti-CLDN18.2 monoclonal antibody HB37A6 (see CN202010570517.X) and the control antibody zolbetuximab (Zmab for short, sequence derived from INN117) were expressed in HEK293 cells (Invitrogen, A14527) in the form of full-length monoclonal antibodies.
  • an expression vector was constructed, and the heavy chain variable region and light chain variable region (see sequence information) of HB37A6 and the control antibody were placed in the human IgG1 heavy chain constant region (SEQ ID NO: 5) and light chain kappa constant region, respectively. (SEQ ID NO: 10) N-terminal. Then construct into pcDNA3.1 expression vector with N-terminal signal peptide to obtain light and heavy chain expression vector. The obtained light and heavy chain expression vectors were co-transfected into HEK293 cells by PEI (Polysciences Inc, 23966), and the culture supernatant was collected after 7 days of culture.
  • PEI Polysciences Inc, 23966
  • the supernatant was purified by Protein A column (Hitrap Mabselect Sure, GE 11-0034-95), then ultrafiltered and exchanged into PBS (Gibco, 70011-044), the concentration was detected by A280 method and the purity was determined by SEC-HPLC method , to obtain an antibody solution with a purity greater than 95%, to obtain a recombinant CLDN18.2 monoclonal antibody HB37A6.
  • Expi293 cells (Invitrogen, A14527) were passaged according to the desired transfection volume, and the cell density was adjusted to 1.5 x 106 cells/ml the day before transfection. The cell density on the day of transfection was approximately 3 x 106 cells/ml. Take 1/10 of the final volume of Opti-MEM medium (Gibco, 31985-070) as the transfection buffer, add the appropriate plasmid to the transfected cells at 1.0 ⁇ g/ml, and mix well.
  • Opti-MEM medium Gibco, 31985-070
  • PEI polyethyleneimine
  • the Protein A column used for purification (Hitrap Mabselect Sure, GE, 11-0034-95) was treated with 0.1M NaOH for 2h, the glass bottle was washed with distilled water, and then dried at 180°C for 4h. Before purification, the collected cell feed was centrifuged at 4500 rpm for 30 min, and the supernatant was filtered through a 0.22 ⁇ m filter. The Protein A column was equilibrated with 10 column volumes of binding buffer (sodium phosphate 20 mM. NaCl 150 mM, pH 7.0). The filtered supernatant was applied to the purification column and equilibrated with 10 column volumes of binding buffer.
  • binding buffer sodium phosphate 20 mM. NaCl 150 mM, pH 7.0
  • elution buffer citric acid + sodium citrate 0.1M, pH 3.5
  • elution buffer citric acid + sodium citrate 0.1M, pH 3.5
  • the collected antibodies were concentrated and exchanged into PBS (Gibco, 70011-044) by ultrafiltration, and the concentration was checked.
  • the equilibrium dissociation constant (K D ) of HB37A6 binding to human CLDN18.2 was determined by surface plasmon resonance (SPR).
  • Human Claudin18.2 (GenScrip, P50251802) was coupled to the surface of a CM5 chip (GE Healthcare, 29-1496-03) using an amino coupling kit (GE Healthcare, BR-1006-33) according to the manufacturer's instructions, After coupling, 1 M ethanolamine was injected to block the remaining activated sites.
  • Affinity and kinetic constants were obtained by detecting the binding and dissociation between the chip surface antigen and the antibody in the mobile phase by Biacore (GE Healthcare, T200) according to the manufacturer's instructions.
  • the serially diluted antibody (0-100nM) was flowed over the chip surface sequentially from low concentration to high concentration, the binding time was 180s, and the dissociation time was 600s.
  • the chip was finally regenerated using 10 mM Glycine pH 1.5 (GE Healthcare, BR-1003-54). Data results were analyzed kinetically using Biacore T200 analysis software in a 1:1 binding model. As shown in Table 1, the affinity of HB37A6 was better than that of the control antibody Zmab.
  • anti-CLDN18.2 monoclonal antibody HB37A6 and control antibody Zmab were determined by flow cytometry (FACS) and the CHO-S cell lines stably transfected with human CLDN18.2 and human CLDN18.1 obtained in Example 1, respectively (ie binding of CHO-hCLDN18.2 and CHO-hCLDN18.1 prepared as described in Example 1).
  • the cells to be detected (CHO-hCLDN18.2 and CHO-hCLDN18.1) obtained in Example 1 were counted, diluted to 1 ⁇ 10 6 cells/ml, and 100 ⁇ l was added to a U-bottom 96-well plate /hole. 500g for 5min, centrifuge to remove cell culture medium.
  • the anti-CLDN18.2 monoclonal antibody HB37A6 and the control antibody Zmab were added to the U-shaped plate and the cells were resuspended. 100 ⁇ l was added to each well.
  • the initial concentration of the antibody was 900 nM, and then diluted 3-fold in sequence, with a total of 10 concentration points. Let stand on ice for 30min.
  • Example 5 the binding of HB37A6 to gastric cancer cell line NUGC-4 (JCRB Cell Bank, JCRB0834), gastric cancer cell line KATO III-hCLDN18.2 and pancreatic cancer cell line DAN-G-hCLDN18.2 was determined by FACS.
  • Figure 3 shows that the fully human antibody HB37A6 has better specific binding to tumor cells than that of the control antibody Zmab.
  • HB37A6 antibody was used to test its antitumor effect in NOD-SCID mice with human pancreatic cancer (female NOD-SCID mice (15-18g) were purchased from Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd., the number of 60) .
  • the human pancreatic cancer cell DAN-G-hCLDN18.2 constructed in Example 1 was routinely subcultured for subsequent in vivo experiments. The cells were collected by centrifugation, and DAN-G-hCLDN18.2 was dispersed in PBS (1 ⁇ ) to obtain a suspension with a cell density of 12 ⁇ 10 ⁇ 5 cells/ml. The cell suspension was mixed with matrigel gel 1:1 to prepare a cell suspension with a cell concentration of 6 ⁇ 10 ⁇ 5 cells/ml. On day 0, 0.2 ml of the cell suspension was subcutaneously inoculated into the right abdominal area of NOD-SCID mice to establish a DAN-G-CLDN18.2 tumor-bearing mouse model.
  • mice with tumor volume ranging from 43.36 mm 3 to 89.47 mm 3 were selected and grouped according to the size of the tumor volume (8 mice in each group).
  • mice were administered hIgG (Equitech-Bio, batch number 160308-02), HB37A6 and the control antibody Zmab, at a dose of 10 mg/kg each time, on the 5th, 9th, 12th, and 16th days after inoculation, respectively.
  • the HB37A6 antibody was selected to test its anti-tumor effect in NOG mice with human gastric cancer (female NOG mice (15-18 g) were purchased from Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd., number 100).
  • the PBMC cells (Allcells) were recovered, centrifuged to collect the cells, and the PBMC cells were dispersed with PBS (1 ⁇ ), the cell density was 2.5 ⁇ 10 ⁇ 6 cells/ml cell suspension, and 0.2ml of the cell suspension was taken on the 0th day for NOG Intravenous injection of mouse eyes to establish NOG humanized mouse model.
  • NUGC-4 cells were routinely recovered and subcultured for subsequent in vivo experiments. Cells were collected by centrifugation, NUGC-4 cells were dispersed with PBS (1 ⁇ ), the cell density was 12 ⁇ 10 ⁇ 6 cells/ml, and matrigel gel was mixed 1:1 to prepare a cell suspension with a cell concentration of 6 ⁇ 10 ⁇ 6 cells/ml . On day 5, 0.2 ml of the cell suspension was subcutaneously inoculated into the right abdominal area of NOG humanized mice to establish a NUCG-4 tumor-bearing mouse model.
  • TGI% 100%*(tumor volume of control group-tumor volume of treatment group)/(tumor volume of control group-tumor volume of control group before administration).
  • HB37A6 and the control antibody Zmab can inhibit tumor growth in the human pancreatic cancer DAN-G-CLDN18.2 mouse model.
  • the TGI of HB37A6 is 28%, and the TGI of Zmab is 24%.
  • HB37A6 showed better anti-tumor effect than the control antibody Zmab in the human gastric cancer NUGC-4 mouse model, the TGI of HB37A6 was 31%, and the TGI of Zmab was 0%.
  • the heavy chain variable region heavy chain variable region and light chain variable region (see sequence information) of HzSP34.24, HzSP34.87, HzSP34.97, sp34 were placed in the IgG1 heavy chain constant region (SEQ ID NO: 23) and the N-terminus of the light chain lambda constant region (SEQ ID NO:28). Then construct into pcDNA3.1 expression vector with N-terminal signal peptide to obtain light and heavy chain expression vector. The obtained light and heavy chain expression vectors were co-transfected into HEK293 cells by PEI (Polysciences Inc, 23966), and the culture supernatant was collected after 7 days of culture.
  • PEI Polysciences Inc, 23966
  • the supernatant was purified by Protein A column (Hitrap Mabselect Sure, GE 11-0034-95), then ultrafiltered and exchanged into PBS (Gibco, 70011-044), the concentration was detected by A280 method and the purity was determined by SEC-HPLC method , to obtain an antibody solution with a purity greater than 95%, to obtain recombinant anti-CD3 monoclonal antibodies HzSP34.24, HzSP34.87, HzSP34.97 and mouse CD3 antibody sp34. See Example 3 for the specific transfection and purification process.
  • Jurkat cells are immortalized human T lymphocytes expressing human CD3 complex, and the binding of the antibodies of the present invention to the cells was detected using this cell line.
  • the detailed operation is as follows: inoculate Jurkat cells (Promega, J1621) in a U-shaped 96-well plate, 2 ⁇ 105 cells per well, and add the antibodies to be detected (anti-CD3 monoclonal antibodies HzSP34.24, HzSP34.87, HzSP34.
  • the humanized CD3 antibody HzSP34.24 showed a comparable affinity to the murine antibody sp34 at the cellular level, while the affinity of Hzsp34.87 and Hzsp34.97 to CD3 at the cellular level was weakened to varying degrees. .
  • the present invention uses Jurkat NFAT (Nuclear Factor of Activated T) reporter cells (Promega, J1621) to detect the T cell activation function of anti-CD3 monoclonal antibodies HzSP34.24, HzSP34.87, HzSP34.97 and mouse-derived CD3 antibody sp34. It is an engineered Jurkat T cell. When the cell is activated through the TCR-CD3 pathway, it releases the luciferase substrate into the experimental system through the downstream signal NFAT, so that the degree of activation of the T cell can be detected.
  • Jurkat NFAT Nuclear Factor of Activated T reporter cells
  • each well mixes 4 ⁇ 10 4 Jurkat NFAT cells with the corresponding concentration of each antibody molecule (the initial concentration of the antibody molecule is 500nM, and the dilution is carried out in a 3-fold gradient), Incubate in a 37°C incubator for 6-8 hours, then add 100 microliters of Bio-Glo (Promega, G7940) to each well, and use a microplate reader (Spectra, Molecular Devices) for wavelength detection.
  • Bio-Glo Promega, G7940
  • a microplate reader Spectra, Molecular Devices
  • the heavy chain variable region sequence of the antigen-binding domain specifically targeting CLDN18.2 is SEQ ID NO: 4, and the light chain variable region sequence is SEQ ID NO: 9; the antigen specifically targeting CD3
  • the heavy chain variable region sequence of the binding domain is: SEQ ID NO:22, SEQ ID NO:30 and SEQ ID NO:32, and the light chain variable region sequence is SEQ ID NO:27.
  • the Fc segment of the antibody was selected from the IgG1 LALA sequence of the knob-hole structure (A. Margaret Merchant et al., Nature Biotechnology, 1998).
  • the heavy chain of the terminal portion of bispecific antibody CLDN18.2 is SEQ ID NO:37 and the light chain is SEQ ID NO:38.
  • the heavy chain of the CD3 terminal portion of the bispecific antibody is SEQ ID NO:39, 41 and 42, respectively, and the light chain is SEQ ID NO:40.
  • the plasmid construction process of the bispecific antibody is as follows: the heavy chain sequence of CLDN18.2 (SEQ ID NO: 37), the light chain sequence of CLDN18.2 (SEQ ID NO: 38), the heavy chain sequence of CD3 (SEQ ID NO: 38) NO: 39, 41 and 42) and the light chain sequence of CD3 (SEQ ID NO: 40) were inserted into the vector pcDNA3.1 (Invitrogen, V790-20) to obtain the heavy chain plasmid and light chain plasmid at the CLDN18.2 end, respectively, Heavy chain plasmid and light chain plasmid at the CD3 end.
  • the heavy chain plasmid at the CLDN18.2 end, the light chain plasmid at the CD3 end and the heavy chain plasmid at the CD3 end were transiently transfected into Expi293 cells (Invitrogen, A14527) using PEI (Polysciences, 23966), respectively, to express the CLDN18.2 end and 3 antibody molecules at the CD3 end.
  • the cell fermentation broth was obtained, clarified by filtration, and captured with the Protein A column of Hitrap Mabselect Sure (GE Healthcare, 11-0034-95) to obtain CLDN18.2-end and CD3-end antibodies.
  • the concentration was detected by the A280 method, the antibodies at both ends were mixed in a molar ratio of 1:1.
  • the equilibrium dissociation constant (KD) of the bispecific antibody of the present invention binding to human CD3 protein was determined by biofilm thin-layer interferometry (BLI).
  • BLI biofilm thin-layer interferometry
  • the BLI method affinity determination was performed according to the existing method (Estep, P et al., High throughput solution Based measurement of antibody-antigen affinity and epitope binning. MAbs, 2013.5(2): pp. 270-8).
  • the instrument setting parameters are as follows: running steps: Baseline, Loading ⁇ 1nm, Baseline, Association and Dissociation; the running time of each step depends on the speed of sample binding and dissociation, the rotation speed is 1000rpm, and the temperature is 30°C. KD values were analyzed using ForteBio Octet analysis software.
  • the affinities of the bispecific antibodies are shown in Table 3. Among them, the CD3 end of 030 molecule had the highest affinity at 7.4nM. The CD3-terminal affinity of 032 and 033 molecules decreased sequentially, which were 89nM and 440nM, respectively.
  • the equilibrium dissociation constant (KD) of human CLDN18.2 was determined by surface plasmon resonance (SPR).
  • the antigen human Claudin18.2 (GenScrip, P50251802) was coupled to the surface of a CM5 chip (GE Healthcare, 29-1496-03) using an amino conjugation kit (GE Healthcare, BR-1006-33) according to the manufacturer's instructions , and injected 1 M ethanolamine after coupling to block the remaining active sites.
  • the affinity and kinetic constants were obtained by detecting the binding and dissociation between the chip surface antigen and each bispecific antibody in the mobile phase by Biacore (GE Healthcare, T200) according to the manufacturer's instructions.
  • the serially diluted antibodies (0-100nM, 2-fold dilution) were sequentially flowed over the chip surface from low concentration to high concentration, the binding time was 180s, and the dissociation time was 600s.
  • the chip was finally regenerated using 10 mM Glycine pH 1.5 (GE Healthcare, BR-1003-54).
  • Data results were analyzed kinetically using Biacore T200 analysis software with a 1:1 binding model. The results are shown in Table 4.
  • the 030, 032 and 033 bispecific antibodies use the same clone HB37A6 at the CLDN18.2 end, and the affinity at the CLDN18.2 end is the same, with a very strong affinity of 0.57nM.
  • PBMC peripheral blood mononuclear cells
  • FBS fetal bovine serum
  • NUGC-4 or Claudin18.2-overexpressing DAN-G tumor target cells DAN-G-hCLDN18.2, non-target cells L363 (DSMZ, ACC49) were labeled with Far-Red (Invitrogen) for 10 min, washed twice and resuspended In complete medium, the cell concentration was adjusted to 2 ⁇ 10 5 cells/ml.
  • PBMCs were mixed with bispecific antibodies 030, 032 and 033 respectively (the initial concentration used for 030, 032 was 1 nM, and the initial concentration used for 033 was 400 nM, all antibodies were diluted 5 times, a total of 10 concentration points), 37 °C After incubation for 30 min, 50 ⁇ l of tumor target cells (1 ⁇ 10 4 ) were added to 50 ⁇ l of PBMC effector cells at a 10:1 effector-to-target ratio.
  • the killing effect of the bispecific antibody of the present invention is related to the abundance of CLDN18.2 on the cell surface. Within a certain expression abundance range, the higher the expression level of CLDN18.2 on the cell surface, the better the killing effect.
  • PBMC peripheral blood mononuclear cells
  • FBS Hyclone, SH30084.03
  • concentration of DAN-G-hCLDN18.2 in NUGC-4 or Claudin18.2-overexpressing DAN-G tumor target cells was adjusted to 2 ⁇ 10 5 cells/ml.
  • PBMCs were mixed with bispecific antibodies 030, 032 and 033, respectively, incubated at 37°C for 30 min, and then 50 ⁇ l of tumor target cells (1 ⁇ 10 4 ) were added to 50 ⁇ l of PBMC effector cells at an effector-target ratio of 10:1. Incubate at 37°C for 24 hours, centrifuge, and take the cell supernatant. Cytokines were detected by Human Th1/Th2/Th17Kit kit (BD, Cat. No. 560484), incubated at room temperature for 3 hours, detected by flow cytometer (BD, FACSCELESTA), and the cytokines in the supernatant were analyzed by FCAP Array software (BD). freed.
  • BD Human Th1/Th2/Th17Kit kit
  • PBMC peripheral blood mononuclear cells
  • FBS fetal bovine serum
  • the concentration of DAN-G-CLDN18.2 in NUGC-4 or Claudin18.2-overexpressing DAN-G tumor target cells was adjusted to 2 ⁇ 10 5 cells/ml.
  • PBMCs were mixed with bispecific antibodies 030, 032 and 033, respectively, incubated at 37°C for 30 min, and then 50 ⁇ l of tumor target cells (1 ⁇ 10 4 ) were added to 50 ⁇ l of PBMC effector cells at an effector-target ratio of 10:1.
  • molecules 30, 032 and 033 could specifically activate T cells in the co-culture of gastric cancer cells NUGC-4, and the activation ability was positively correlated with the affinity of CD3 terminal.
  • Example 16 In vivo efficacy test - gastric cancer model
  • This experiment investigated the antitumor effect of bispecific antibody on NUGC-4 tumor bearing in NOG female mice. 49 NOG female mice (Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd.) were selected.
  • the PBMC cells (Allcells) were recovered, the cells were centrifuged, and the PBMC cells were dispersed with PBS (1 ⁇ ) to obtain a cell suspension with a cell density of 2 ⁇ 10 7 /ml. Take 200 ⁇ l of cell suspension and inject PBMC cells into the orbital vein of mice, 4 ⁇ 10 6 / mouse.
  • NUGC-4 cells were routinely recovered and subcultured for subsequent in vivo experiments. Cells were collected by centrifugation, NUGC-4 cells were dispersed with PBS (1 ⁇ ), the cell density was 6 ⁇ 10 7 cells/ml, and the cells were mixed with matrigel gel 1:1 to prepare a cell suspension with a cell concentration of 3 ⁇ 10 7 cells/ml. On day 3, 0.2 ml of the cell suspension was subcutaneously inoculated into the right abdominal region of NOG humanized mice to establish a NUCG-4 tumor-bearing mouse model.
  • mice On the 7th day after cell inoculation, use a vernier caliper to measure the largest wide axis and largest long axis of the mouse tumor, calculate the tumor volume, select the mouse with a tumor volume within 53.35mm 3 ⁇ 168.07mm 3 , and carry out snake shape according to the mouse tumor volume Groups (6 mice per group).
  • Each mouse was intravenously injected with bispecific antibodies 030, 032 and 033 of the present invention, and a negative control h-IgG (Equitech-Bio, batch number 160308-02) at a dose of 0.3 mg/kg and 1 mg/kg, It was administered once a week for a total of 4 times, and the frequency of measuring the tumor volume in mice was twice a week.
  • TGI% tumor inhibition rate
  • TGI% 100%*(tumor volume of control group-tumor volume of treatment group)/(tumor volume of control group-tumor volume of control group before administration).
  • 030 and 032 can achieve 100% TGI at the low dose of 0.3 mg/kg, and even achieve 50% CR at the high dose of 1 mg/kg (complete remission) (3 out of 6 mice achieved complete tumor eradication).
  • the 033 molecule has almost no efficacy at low doses, and at a dose of 1 mg/kg, the TGI can reach 20%.
  • the body weight of the mice in the experimental group and the control group did not decrease.
  • Example 17 In vivo efficacy experiment—pancreatic cancer model
  • NOG female mice 49 NOG mice (Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd.) were injected with PBMC cells by orbital vein, 4 ⁇ 10 6 /mice, and the inoculation volume was 200ul /mice (as shown in Example 18). This time is recorded as day 0.
  • the human pancreatic cancer cell DAN-G-CLDN18.2 constructed in Example 1 was routinely subcultured for subsequent in vivo experiments.
  • the cells were collected by centrifugation, and DAN-G-CLDN18.2 was dispersed in PBS (1 ⁇ ) to obtain a suspension with a cell density of 10 ⁇ 10 6 cells/ml.
  • the cell suspension was mixed with matrigel gel 1:1 to prepare a cell suspension with a cell concentration of 5 ⁇ 10 6 cells/ml.
  • 0.2 ml of the cell suspension was subcutaneously inoculated into the right abdominal area of NOD-SCID mice to establish a DNA-G pancreatic cancer humanized model overexpressing CLDN18.2.
  • the bispecific antibodies 030, 032 and 033 of the present invention, and the negative control h-IgG (Equitech-Bio, Lot No. 160308-02) were intravenously injected into each mouse at a dose of 0.3 mg/kg and 1 mg/kg intraperitoneally , administered once a week for a total of 4 times, and the frequency of measuring the tumor volume in mice was twice a week.
  • the tumor inhibition rate (TGI%) was calculated, and the calculation formula was as follows:
  • TGI% 100%*(tumor volume of control group-tumor volume of treatment group)/(tumor volume of control group-tumor volume of control group before administration).
  • both 030 and 032 molecules could achieve TGI of 100% at both doses.
  • the 033 molecule also reached TGI 42% (0.3mg/kg) and TGI 76% (1mg/kg), which may be related to the high expression of CLDN18.2 in DAN-G-CLDN18.2 pancreatic cancer cells.
  • TGI 42% 0.3mg/kg
  • TGI 76% (1mg/kg
  • mice Female Balb/C mice (Vitronilever) by tail vein administration to study their pharmacokinetic properties in mice.
  • blood was collected from the eyeball at 0.086hr, 0.5hr, 2hr, 6hr, 24hr, 48hr, 4day, 7day, 14day and 21day, respectively.
  • the blood was centrifuged at 3000 rpm at 4°C for 10 min to collect serum.
  • the antibody content in serum was determined by ELISA, and the half-lives of 030, 032 and 033 in mice were obtained by calculation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/CN2021/121286 2020-09-29 2021-09-28 抗Claudin18.2和CD3的双特异性抗体以及其用途 Ceased WO2022068810A1 (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2021352532A AU2021352532B2 (en) 2020-09-29 2021-09-28 Anti-claudin18.2 and cd3 bispecific antibody and use thereof
CN202180066494.1A CN116323676A (zh) 2020-09-29 2021-09-28 抗Claudin18.2和CD3的双特异性抗体以及其用途
US18/246,939 US20230357389A1 (en) 2020-09-29 2021-09-28 Anti-claudin18.2 and cd3 bispecific antibody and use thereof
JP2023519492A JP2023544143A (ja) 2020-09-29 2021-09-28 抗クローディン１８．２および抗ｃｄ３二重特異性抗体およびその使用
EP21874470.4A EP4223778A4 (en) 2020-09-29 2021-09-28 BISPECIFIC ANTIBODY TO CLAUDIN 18.2 AND CD3 AND ITS USE
KR1020237014540A KR20230079165A (ko) 2020-09-29 2021-09-28 항-클라우딘18.2 및 cd3 이특이적 항체 및 이의 용도
CA3200865A CA3200865A1 (en) 2020-09-29 2021-09-28 Anti-claudin18.2 and cd3 bispecific antibody and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011054428.6 2020-09-29
CN202011054428 2020-09-29

Publications (1)

Publication Number Publication Date
WO2022068810A1 true WO2022068810A1 (zh) 2022-04-07

Family

ID=80949663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/121286 Ceased WO2022068810A1 (zh) 2020-09-29 2021-09-28 抗Claudin18.2和CD3的双特异性抗体以及其用途

Country Status (9)

Country Link
US (1) US20230357389A1 (https=)
EP (1) EP4223778A4 (https=)
JP (1) JP2023544143A (https=)
KR (1) KR20230079165A (https=)
CN (1) CN116323676A (https=)
AU (1) AU2021352532B2 (https=)
CA (1) CA3200865A1 (https=)
TW (1) TWI837517B (https=)
WO (1) WO2022068810A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116813782A (zh) * 2023-08-10 2023-09-29 北京百普赛斯生物科技股份有限公司 一种Claudin-18.2特异性抗体及其应用
WO2023185732A1 (zh) * 2022-03-28 2023-10-05 信达生物制药（新加坡）有限公司 包含抗Claudin18.2和CD3双特异性抗体的制剂及其制备方法和用途
WO2023241656A1 (zh) * 2022-06-15 2023-12-21 中山康方生物医药有限公司 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用
WO2025223376A1 (zh) * 2024-04-22 2025-10-30 鲁南新时代生物技术有限公司 抗cldn18.2/cd3双特异性抗体及用途
JP2026501244A (ja) * 2022-12-23 2026-01-14 ワイ－バイオロジクス・インコーポレイテッド クローディン１８．２に特異的に結合する単クローン抗体及びその用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
CN104968367A (zh) * 2012-11-13 2015-10-07 弗·哈夫曼-拉罗切有限公司 抗血凝素抗体和使用方法
CN105073776A (zh) * 2012-11-13 2015-11-18 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
WO2018219901A1 (en) * 2017-06-01 2018-12-06 F. Hoffmann-La Roche Ag Treatment method
WO2019075405A1 (en) * 2017-10-14 2019-04-18 Cytomx Therapeutics, Inc. ANTIBODIES, ACTIVISTIC ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFICALLY ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF
WO2019213331A1 (en) * 2018-05-01 2019-11-07 Ambrx, Inc. A method for optimizing antibody expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3766903A3 (en) * 2012-11-13 2021-02-17 BioNTech SE Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
EP3577137A1 (en) * 2017-02-02 2019-12-11 Merck Patent GmbH Preferred pairing of antibody domains
SG11201907422RA (en) * 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
WO2019242505A1 (zh) * 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
WO2020025792A1 (en) * 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Antibody constructs for cldn18.2 and cd3

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
CN104968367A (zh) * 2012-11-13 2015-10-07 弗·哈夫曼-拉罗切有限公司 抗血凝素抗体和使用方法
CN105073776A (zh) * 2012-11-13 2015-11-18 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
WO2018219901A1 (en) * 2017-06-01 2018-12-06 F. Hoffmann-La Roche Ag Treatment method
WO2019075405A1 (en) * 2017-10-14 2019-04-18 Cytomx Therapeutics, Inc. ANTIBODIES, ACTIVISTIC ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFICALLY ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF
WO2019213331A1 (en) * 2018-05-01 2019-11-07 Ambrx, Inc. A method for optimizing antibody expression

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", 1989, JOHN WILEY & SONS
"UniProt", Database accession no. P56856-2
A. MARGARET MERCHANT ET AL., NATURE BIOTECHNOLOGY, 1998
AL-LAZIKANI ET AL.: "Standard conformations for the canonical structures of immunoglobulins", JOURNAL OF MOLECULAR BIOLOGY, vol. 273, 1997, pages 927 - 948, XP004461383, DOI: 10.1006/jmbi.1997.1354
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883
E. MEYERSW. MILLER: "ALIGN program", CABIOS, vol. 4, 1989, pages 11 - 17
ESTEP, P ET AL.: "High throughput solution based measurement of antibody-antigen affinity and affinity binding", MABS, vol. 5, no. 2, 2013, pages 270 - 8, XP055105281, DOI: 10.4161/mabs.23049
FAN ET AL., JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 8, 2015, pages 130
GUOYUN ZHU, FOLETTI DAVIDE, LIU XIAOHUI, DING SHENG, MELTON WITT JODY, HASA-MORENO ADELA, RICKERT MATHIAS, HOLZ CHARLES, ASCHENBRE: "Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer", SCIENTIFIC REPORTS, vol. 9, no. 1, 1 January 2019 (2019-01-01), pages 1 - 11, XP055630964, DOI: 10.1038/s41598-019-44874-0 *
J. IMMUNOL. METHODS., vol. 178, 1994, pages 195
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KABAT ET AL.: "U.S. Department of Health and Human Services, National Institutes of Health (1987)), AbM", UNIVERSITY OF BATH, article "Sequences of Proteins of Immunological Interest"
NEEDLEMAWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453
O. TURECI. ET AL., GENE, vol. 481, 2011, pages 83 - 92
ROOT ADAM, CAO WEI, LI BILIAN, LAPAN PETER, MEADE CARYL, SANFORD JOCELYN, JIN MACY, O’SULLIVAN CLIONA, CUMMINS EMMA, LAMBERT MATTH: "Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer", ANTIBODIES, vol. 5, no. 1, 4 March 2016 (2016-03-04), XP055920294, DOI: 10.3390/antib5010006 *
See also references of EP4223778A4
SHANE ATWELL ET AL., JOURNAL OF MOLECULAR BIOLOGY, 1997
SINGH, P.TOOM, S.HUANG, Y.: "Anti-CLDN18.2 antibody as new targeted therapy for advanced gastric cancer", J HEMATOL ONCOL, vol. 10, 2017, pages 105, Retrieved from the Internet <URL:https://doi.org/10.1186/s13045-017-0473-4>

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023185732A1 (zh) * 2022-03-28 2023-10-05 信达生物制药（新加坡）有限公司 包含抗Claudin18.2和CD3双特异性抗体的制剂及其制备方法和用途
EP4501313A4 (en) * 2022-03-28 2026-03-25 Fortvita Biologics Singapore Pte Ltd Preparations containing a bispecific anti-Claudin 18.2/CD3 antibody, their preparation method and use
WO2023241656A1 (zh) * 2022-06-15 2023-12-21 中山康方生物医药有限公司 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
JP2026501244A (ja) * 2022-12-23 2026-01-14 ワイ－バイオロジクス・インコーポレイテッド クローディン１８．２に特異的に結合する単クローン抗体及びその用途
CN116813782A (zh) * 2023-08-10 2023-09-29 北京百普赛斯生物科技股份有限公司 一种Claudin-18.2特异性抗体及其应用
CN116813782B (zh) * 2023-08-10 2024-01-23 北京百普赛斯生物科技股份有限公司 一种Claudin-18.2特异性抗体及其应用
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用
WO2025223376A1 (zh) * 2024-04-22 2025-10-30 鲁南新时代生物技术有限公司 抗cldn18.2/cd3双特异性抗体及用途

Also Published As

Publication number Publication date
EP4223778A4 (en) 2024-11-06
KR20230079165A (ko) 2023-06-05
AU2021352532B2 (en) 2026-01-15
CN116323676A (zh) 2023-06-23
AU2021352532A1 (en) 2023-05-25
US20230357389A1 (en) 2023-11-09
JP2023544143A (ja) 2023-10-20
AU2021352532A9 (en) 2025-03-13
EP4223778A1 (en) 2023-08-09
TW202216783A (zh) 2022-05-01
TWI837517B (zh) 2024-04-01
CA3200865A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
TWI809426B (zh) 抗Ｃｌａｕｄｉｎ１８.２抗體以及其用途
TWI837517B (zh) 抗claudin 18.2和cd3的雙特異性抗體以及其用途
TWI793395B (zh) 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
WO2020135201A1 (zh) 一种抗体及其用途
CN116261590B (zh) 抗cd3抗体以及其用途
TWI756621B (zh) 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
JP2025522557A (ja) Ｅｇｆｒおよびｂ７－ｈ３に結合する二重特異性抗体
WO2020156439A1 (zh) 抗cd79b抗体、其抗原结合片段及其医药用途
CN118852442A (zh) 抗ptk7抗体及其用途
CN120603848A (zh) 三特异性抗原结合分子及其应用
WO2021175191A1 (zh) 抗tim-3抗体及其用途
JP2023521790A (ja) 抗ｃｄ４７抗体およびその使用
HK40083793A (en) Anti-claudin18.2 antibody and use thereof
WO2025201493A1 (zh) Dll3结合分子及其用途
CN120659811A (zh) 双特异性抗原结合分子及其应用
CN120818052A (zh) 抗il-15抗体以及其用途
CN120329439A (zh) 一种单克隆抗体及其应用
HK40048164B (zh) 一种抗体及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21874470

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023519492

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3200865

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20237014540

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021874470

Country of ref document: EP

Effective date: 20230502

ENP Entry into the national phase

Ref document number: 2021352532

Country of ref document: AU

Date of ref document: 20210928

Kind code of ref document: A